Ranibizumab

also known as Lucentis · rhuFab V2 · RBZ · FYB201 · Lucentis = ranibizumab · Ranibizumab (Lucentis) · RFB002 · (Lucentis, Ranibizumab (Novartis Pharma AG, Basel, Switzerland, and Genentech Inc., South San Francisco, CA, USA) · +9 more

Monoclonal antibody targets VEGFA via inhibition

Developed for: diabetic macular edema · age-related macular degeneration · wet macular degeneration · choroidal neovascularization · macular retinal edema · retinal vein occlusion · macular degeneration · proliferative diabetic retinopathy
+49 more
· diabetic retinopathy · occlusion of tributary of retinal vein · central retinal vein occlusion · perifoveal exudative vascular anomalous complex · cystoid macular edema · neovascular glaucoma · diabetes mellitus · retinopathy of prematurity · vision disorder · glaucoma · retinal detachment · retinal vascular disorder · rubeosis iridis · degenerative myopia · malignant choroid melanoma · von Hippel-Lindau disease · central retinal vein occlusion with macular edema · corneal neovascularization · macular telangiectasia · pterygium · telangiectasis · uveitis · angioid streaks · central serous chorioretinopathy · Coats disease · conjunctival pterygium · conjunctival tumor · degeneration of macula and posterior pole · Eales disease · hereditary hemorrhagic telangiectasia · histoplasmosis retinitis · inherited retinal dystrophy · macular telangiectasia type 2 · multifocal choroiditis · myopia · neurofibroma · neurofibromatosis type 1 · non-arteritic anterior ischemic optic neuropathy · perinatal disease · preretinal fibrosis · pseudoxanthoma elasticum (inherited or acquired) · retinal disorder · retinal telangiectasia · retinoblastoma · toxic maculopathy · vitelliform macular dystrophy · ischemic disease · macular holes · myopic macular degeneration
Investigated by: Genentech, Inc. · Novartis Pharmaceuticals · Novartis · National Eye Institute (NEI) · Hoffmann-La Roche · Johns Hopkins University
+225 more
· University of Sao Paulo · Sun Yat-sen University · University of Miami · Allergan · Jaeb Center for Health Research · Juvenile Diabetes Research Foundation · University Hospital, Bonn · Vitreous -Retina- Macula Consultants of New York · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Moorfields Eye Hospital NHS Foundation Trust · Nagoya City University · Novartis · Oregon Health and Science University · QLT Inc. · Southeast Retina Center, Georgia · University of California, San Diego · University of Illinois at Chicago · University of Luebeck · Barnes Retina Institute · Bay Area Retina Associates · Beijing Hospital · Charles C Wykoff, PhD, MD · David M. Brown, M.D. · Eye & ENT Hospital of Fudan University · Insel Gruppe AG, University Hospital Bern · Instituto de Olhos de Goiania · JUNYAN ZHANG · King's College Hospital NHS Trust · Kyungpook National University Hospital · Kyushu University · Medical University of Vienna · Mie University · New England Retina Associates · Opthea Limited · Peter A Campochiaro, MD · Pusan National University Hospital · Quark Pharmaceuticals · Retina Associates of Florida, P.A. · Samsung Medical Center · Seoul National University Hospital · Shanghai 10th People's Hospital · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · São Paulo Research Foundation · The First People's Hospital of Xuzhou · The New York Eye & Ear Infirmary · The New York Eye Cancer Center · University of California, San Francisco · University of Colorado, Denver · Vista Klinik · AO GENERIUM · AbbVie · Aerpio Therapeutics · Affiliated Hospital of Nantong University · Aier School of Ophthalmology, Central South University · Asahikawa Medical College · Asociación para Evitar la Ceguera en México · Association for Innovation and Biomedical Research on Light and Image · Astellas Pharma Europe B.V. · Autonomous University of San Luis Potosí · Beckman Laser Institute University of California Irvine · Benha University · Bhagat, Neelakshi, M.D., M.P.H. · Bioeq GmbH · Brian Burke, MPH · California Pacific Medical Center · California Retina Consultants · Canadian National Institute for the Blind · Cangzhou Eye Hospital · Centro Medico Issemym · Centro Medico Teknon · Centro de Retina Medica y Quirurgica S.C. · Charite University, Berlin, Germany · Chungnam National University Hospital · Clinical Research Support Center Kyush · all 231 on the full record

Regulatory milestones approvals, filings & regulatory actions · 13 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (2)	US (FDA)	SUSVIMO	—	2025-02-03 – 2025-05-21	fda.gov ↗
Label expansions (9)	US (FDA)	LUCENTIS	—	2008-04-23 – 2017-04-15	fda.gov ↗
Approved	EU (EMA)	Lucentis	—	2007-01-22	europa.eu ↗
Approved	US (FDA)	LUCENTIS	—	2006-06-30	fda.gov ↗

Trials 318 · started per year

today

US approved 2006

EU approved 2007

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT06205979	Dec 2023 → Jun 2024	diabetic macular edema	Sohag University	Unknown	No outcome recorded
Phase 0	NCT00657202	Mar 2008 → Oct 2009	neurofibroma, neurofibromatosis type 1	Massachusetts General Hospital	Completed	No outcome recorded
Phase 0	NCT00517010	May 2007 → Jun 2010	age-related macular degeneration	University of California, Davis	Completed	No outcome recorded
Phase 134 trials
Phase 1	NCT05248334	Apr 2022 → Dec 2024	diabetic retinopathy	Tianjin Medical University Eye Hospital	Unknown	No outcome recorded
Phase 1	NCT04878835	May 2018 → Apr 2020	conjunctival pterygium	Universiti Sains Malaysia	Completed	No outcome recorded
Phase 1	NCT02530918	Jul 2015 → Jan 2018	diabetic macular edema, wet macular degeneration	Daiichi Sankyo	Completed	No outcome recorded
Phase 1	NCT02543229	Jul 2015 → Feb 2017	age-related macular degeneration, ocular vascular disorder	Opthea Limited	Completed	No outcome recorded
Phase 1	NCT02294656	Nov 2014 → Sep 2018	cystoid macular edema	Soll Eye	Completed	No outcome recorded
Phase 1	NCT01968486	Jun 2012 → Jul 2013	degenerative myopia	University of Campania Luigi Vanvitelli	Completed	No outcome recorded
Phase 1	NCT01406639	Jul 2011 → May 2012	hereditary hemorrhagic telangiectasia	University of California, San Diego	Withdrawn	No outcome recorded
Phase 1	NCT01169909	Aug 2010 → Jul 2014	pterygium	University of New Mexico	Completed	No outcome recorded
Phase 1	NCT01186432	Aug 2010 → May 2012	age-related macular degeneration	Forsight Vision4	Completed	No outcome recorded
Phase 1	NCT01011374	Nov 2009 → Nov 2012	central retinal vein occlusion, depressive disorder, occlusion of tributary of retinal vein	Retina Associates of Cleveland, Inc	Unknown	No outcome recorded
Phase 1	NCT00769145	Oct 2008 → Aug 2011	corneal neovascularization	University of Miami	Completed	No outcome recorded
Phase 1	NCT00750399	Oct 2008 → Sep 2011	malignant choroid melanoma, retinal vascular disorder	The New York Eye Cancer Center	Completed	No outcome recorded
Phase 1	NCT00768963	Oct 2008 → Nov 2011	pterygium	University of Miami	Completed	No outcome recorded
Phase 1	NCT00826618	Jun 2008 → Sep 2012	cystoid macular edema	University of Miami	Completed	No outcome recorded
Phase 1	NCT00765921	Jun 2008 → Feb 2016	malignant choroid melanoma	Massachusetts Eye and Ear Infirmary	Completed	No outcome recorded
Phase 1	NCT00685854	May 2008 → Mar 2011	macular telangiectasia	National Eye Institute (NEI)	Completed	No outcome recorded
Phase 1	NCT00685503	May 2008 → Apr 2011	choroidal neovascularization	National Eye Institute (NEI)	Completed	No outcome recorded
Phase 1	NCT00681889	Apr 2008 → Sep 2009	corneal neovascularization	Reza Dana, MD	Completed	No outcome recorded
Phase 1	NCT00676559	Apr 2008 → Apr 2009	diabetic macular edema	Johns Hopkins University	Withdrawn	No outcome recorded
Phase 1	NCT00726466	Mar 2008 → ?	age-related macular degeneration, choroidal neovascularization	Vitreous -Retina- Macula Consultants of New York	Withdrawn	No outcome recorded
Phase 1	NCT00667472	Mar 2008 → Nov 2013	—	University of California, Irvine	Withdrawn	No outcome recorded
Phase 1	NCT00561834	Nov 2007 → Apr 2009	non-arteritic anterior ischemic optic neuropathy	University of Colorado, Denver	Completed	No outcome recorded
Phase 1	NCT00500344	Jul 2007 → Mar 2009	age-related macular degeneration	Washington University School of Medicine	Completed	No outcome recorded
Phase 1	NCT01069341	Jul 2007 → Dec 2011	proliferative diabetic retinopathy, rubeosis iridis	Bhagat, Neelakshi, M.D., M.P.H.	Completed	No outcome recorded
Phase 1	NCT00457145	Mar → Oct 2007	telangiectasis	National Eye Institute (NEI)	Completed	No outcome recorded
Phase 1	NCT00457067	Mar → Oct 2007	macular telangiectasia	National Eye Institute (NEI)	Completed	No outcome recorded
Phase 1	NCT00456495	Mar 2007 → Sep 2010	conjunctival tumor	The New York Eye Cancer Center	Completed	No outcome recorded
Phase 1	NCT00424710	Jan 2007 → Sep 2010	perifoveal exudative vascular anomalous complex	Hawaii Pacific Health	Completed	No outcome recorded
Phase 1	NCT00403039	Nov 2006 → Dec 2011	retinal vein occlusion	Vitreous -Retina- Macula Consultants of New York	Completed	No outcome recorded
Phase 1	NCT00378196	Sep 2006 → Sep 2007	telangiectasis	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT00363168	Aug 2006 → Jun 2008	choroidal neovascularization	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT00403325	Aug 2006 → ?	central serous chorioretinopathy	Vitreous -Retina- Macula Consultants of New York	Completed	No outcome recorded
Phase 1	NCT00089765	Aug 2004 → Aug 2007	von Hippel-Lindau disease	National Eye Institute (NEI)	Completed	No outcome recorded
Phase 1	NCT00570726	Jun 2000 → Nov 2007	open-angle glaucoma	The New York Eye & Ear Infirmary	Completed	No outcome recorded

Phase 1/227 trials
Phase 1/2	NCT04567303	Oct 2020 → Aug 2026 overdue	macular degeneration	Hoffmann-La Roche	Active not recruiting	No outcome recorded
Phase 1/2	NCT02859441	Jan 2017 → Jul 2019	von Hippel-Lindau disease	National Eye Institute (NEI)	Completed	No outcome recorded
Phase 1/2	NCT03973138	Jan 2015 → Jan 2020	diabetic macular edema	Sun Yat-sen University	Unknown	No outcome recorded
Phase 1/2	NCT01982435	Jun 2014 → May 2016	diabetic macular edema	Justis Ehlers	Completed	No outcome recorded
Phase 1/2	NCT02121353	Nov 2013 → Jan 2016	age-related macular degeneration	Pfenex, Inc	Completed	No outcome recorded
Phase 1/2	NCT01845844	Apr 2013 → Jan 2015	diabetic macular edema	Southeast Retina Center, Georgia	Unknown	No outcome recorded
Phase 1/2	NCT01552408	Mar 2012 → May 2017	diabetic macular edema	David M. Brown, M.D.	Completed	No outcome recorded
Phase 1/2	NCT01471691	Nov 2011 → Feb 2014	central retinal vein occlusion, macular retinal edema, occlusion of tributary of retinal vein	Hanscom, Thomas, M.D.	Completed	No outcome recorded
Phase 1/2	NCT01469156	Sep 2011 → Feb 2015	perifoveal exudative vascular anomalous complex	Southeast Retina Center, Georgia	Completed	No outcome recorded
Phase 1/2	NCT01746563	May 2011 → Aug 2012	diabetic retinopathy	University of Sao Paulo	Completed	No outcome recorded
Phase 1/2	NCT01292798	Mar 2011 → Apr 2013	diabetic macular edema	California Retina Consultants	Completed	No outcome recorded
Phase 1/2	NCT01248117	Nov 2010 → Dec 2012	perifoveal exudative vascular anomalous complex	Retina Consultants of Hawaii	Unknown	No outcome recorded
Phase 1/2	NCT01175395	Sep 2010 → Jan 2013	age-related macular degeneration, choroidal neovascularization	University of Illinois at Chicago	Completed	No outcome recorded
Phase 1/2	NCT01015495	Dec 2009 → Dec 2010	angioid streaks	University of Illinois at Chicago	Withdrawn	No outcome recorded
Phase 1/2	NCT01003106	Nov 2009 → Apr 2015	retinal vein occlusion	Peter A Campochiaro, MD	Completed	No outcome recorded
Phase 1/2	NCT00993525	Sep 2008 → Mar 2010	proliferative diabetic retinopathy	University of Sao Paulo	Unknown	No outcome recorded
Phase 1/2	NCT00661583	Apr 2008 → Sep 2014	glaucoma	University of Colorado, Denver	Completed	No outcome recorded
Phase 1/2	NCT00727038	Jan 2008 → May 2009	neovascular glaucoma	University of Illinois at Chicago	Withdrawn	No outcome recorded
Phase 1/2	NCT00606138	Jan 2008 → Oct 2010	proliferative diabetic retinopathy	Rush University Medical Center	Completed	No outcome recorded
Phase 1/2	NCT00793923	Jan 2008 → Jan 2012	wet macular degeneration	Subhransu K. Ray, M.D., Ph.D.	Completed	No outcome recorded
Phase 1/2	NCT00498355	Jul 2007 → Jan 2009	cystoid macular edema, uveitis	University of California, San Francisco	Completed	No outcome recorded
Phase 1/2	NCT00470977	May 2007 → Dec 2010	Coats disease, degenerative myopia, multifocal choroiditis, perifoveal exudative vascular anomalous complex +4	Manhattan Eye, Ear & Throat Hospital	Completed	No outcome recorded
Phase 1/2	NCT00467935	Mar → Nov 2007	macular degeneration	Retina Research Foundation	Completed	No outcome recorded
Phase 1/2	NCT00570193	Dec 2006 → Jun 2011	age-related macular degeneration, choroidal neovascularization	Mid-Atlantic Retina Consultations, Inc.	Completed	No outcome recorded
Phase 1/2	NCT00837330	May 2006 → Dec 2010	perifoveal exudative vascular anomalous complex	Southeast Retina Center, Georgia	Completed	No outcome recorded
Phase 1/2	NCT00284089	Apr 2005 → Mar 2007	age-related macular degeneration	Novartis	Completed	No outcome recorded
Phase 1/2	NCT00056823	Mar 2003 → Dec 2005	age-related macular degeneration	Genentech, Inc.	Completed	No outcome recorded

Phase 266 trials
Phase 2	NCT05151744	Dec 2021 → Apr 2024	diabetic macular edema	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT04667910	Jan 2021 → Nov 2022	central retinal vein occlusion	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT03927690	May 2019 → Jun 2022	diabetic macular edema	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT03499223	Apr 2018 → Jul 2019	diabetes mellitus, diabetic macular edema	Oxurion	Completed	No outcome recorded
Phase 2	NCT03071055	Oct 2017 → Jun 2019	wet macular degeneration	Southeast Clinical Research Associates, LLC	Completed	No outcome recorded
Phase 2	NCT03423823	Jul 2017 → Jun 2020	wet macular degeneration	Kapil Kapoor	Completed	No outcome recorded
Phase 2	NCT05571267	Oct 2016 → Apr 2018	wet macular degeneration	IVERIC bio, Inc.	Terminated	No outcome recorded
Phase 2	NCT02511067	Oct 2016	diabetic macular edema	University of Nebraska	Withdrawn	No outcome recorded
Phase 2	NCT02387957	Apr 2016 → Jan 2017	age-related macular degeneration	Ophthotech Corporation	Terminated	No outcome recorded
Phase 2	NCT02510794	Sep 2015 → Apr 2018	macular degeneration	Genentech, Inc.	Completed	No outcome recorded
Phase 2	NCT02484690	Aug 2015 → Sep 2017	choroidal neovascularization	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT03763227	Jul 2015 → Aug 2019	inherited retinal dystrophy	Sultan Qaboos University	Completed	No outcome recorded
Phase 2	NCT02358889	Feb 2015 → Sep 2016	age-related macular degeneration, choroidal neovascularization	Iconic Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT02302079	Jan 2015 → Aug 2016	diabetes mellitus, diabetic macular edema	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 2	NCT02222610	Sep 2014 → Mar 2019	retinal vascular disorder	Greater Houston Retina Research	Completed	No outcome recorded
Phase 2	NCT02134457	Aug 2014 → Jan 2017	retinopathy of prematurity	University Hospital Freiburg	Completed	No outcome recorded
Phase 2	NCT01945866	Feb 2014 → Jun 2017	diabetic macular edema	Jaeb Center for Health Research	Completed	No outcome recorded
Phase 2	NCT02050828	Jan 2014 → Apr 2015	diabetic macular edema	Aerpio Therapeutics	Completed	No outcome recorded
Phase 2	NCT01968239	Oct 2013 → Jun 2016	occlusion of tributary of retinal vein	University of Leipzig	Completed	No outcome recorded
Phase 2	NCT01899066	Jul 2013 → Dec 2015	retinoblastoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 2	NCT01914159	Feb 2013 → Mar 2016	age-related macular degeneration	University Hospital, Bonn	Completed	No outcome recorded
Phase 2	NCT01594281	Dec 2012 → Nov 2016	proliferative diabetic retinopathy	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01414153	Aug 2012 → May 2015	wet macular degeneration	Lpath, Inc.	Completed	No outcome recorded
Phase 2	NCT01564108	May 2012 → Jun 2014	cystoid macular edema, steroid-induced glaucoma - borderline	Moorfields Eye Hospital NHS Foundation Trust	Completed	No outcome recorded
Phase 2	NCT01610557	May 2012 → Feb 2015	diabetic macular edema	National Eye Institute (NEI)	Completed	No outcome recorded
Phase 2	NCT01565148	Feb 2012 → Feb 2014	diabetic macular edema	Johns Hopkins University	Terminated	No outcome recorded
Phase 2	NCT01445899	Feb 2012 → Nov 2013	choroidal neovascularization, diabetic macular edema	Quark Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01476449	Nov 2011 → Sep 2016	diabetic macular edema	Retina Vitreous Associates of Florida	Completed	No outcome recorded
Phase 2	NCT01823965	Oct 2011 → Jul 2014	diabetic macular edema	Poitiers University Hospital	Completed	No outcome recorded
Phase 2	NCT01253694	Mar 2011 → Jun 2012	diabetic macular edema	New England Retina Associates	Withdrawn	No outcome recorded
Phase 2	NCT01247220	Nov 2010 → May 2014	macular retinal edema, occlusion of tributary of retinal vein	Retina Associates of Florida, P.A.	Completed	No outcome recorded
Phase 2	NCT01205035	Oct 2010 → Oct 2012	retinal telangiectasia	Eye Center of Northern Colorado, P.C.	Completed	No outcome recorded
Phase 2	NCT01280929	Sep 2010 → Dec 2013	proliferative diabetic retinopathy	José Cunha-Vaz	Completed	No outcome recorded
Phase 2	NCT01122511	Aug 2010 → May 2011	age-related macular degeneration, choroidal neovascularization	Allergan	Terminated	No outcome recorded
Phase 2	NCT01112085	Apr 2010 → Jan 2014	diabetic macular edema	Especialistas en Retina Medica y Quirurgica Grupo de Investigacion	Completed	No outcome recorded
Phase 2	NCT01487629	Apr 2010 → Sep 2012	diabetic retinopathy, macular retinal edema	University of Sao Paulo	Unknown	No outcome recorded
Phase 2	NCT01077401	Feb 2010 → Mar 2012	diabetic macular edema	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT01037348	Jan 2010 → May 2012	choroidal neovascularization	Novartis	Completed	No outcome recorded
Phase 2	NCT00713518	Nov 2009 → Nov 2010	age-related macular degeneration	Quark Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00846625	Nov 2009 → Aug 2011	macular retinal edema, uveitis	University of Utah	Withdrawn	No outcome recorded
Phase 2	NCT00901186	Nov 2009 → Aug 2012	diabetic macular edema, vision disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00896779	Oct 2009 → Sep 2013	macular degeneration	Steven R. Sanislo	Completed	No outcome recorded
Phase 2	NCT01123564	Aug 2009 → Sep 2011	macular retinal edema, retinal vein occlusion	University of Pecs	Unknown	No outcome recorded
Phase 2	NCT00831350	Apr 2009 → Jul 2011	retinal vein occlusion, vitreous detachment	Barnes Retina Institute	Completed	No outcome recorded
Phase 2	NCT01102946	Feb 2009 → Feb 2011	diabetic retinopathy	University of Sao Paulo	Completed	No outcome recorded
Phase 2	NCT01201161	Dec 2008 → Jan 2010	diabetic retinopathy, retinal detachment	University of Sao Paulo	Completed	No outcome recorded
Phase 2	NCT00841581	Dec 2008 → Sep 2011	retinal detachment	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Completed	No outcome recorded
Phase 2	NCT00805233	Dec 2008 → Sep 2010	age-related macular degeneration	Oregon Health and Science University	Completed	No outcome recorded
Phase 2	NCT00815360	Feb 2008 → Jul 2011	diabetic macular edema	Retina Associates of Florida, P.A.	Completed	No outcome recorded
Phase 2	NCT00574093	Jan 2008 → Jun 2009	wet macular degeneration	Fondazione G.B. Bietti, IRCCS	Completed	No outcome recorded
Phase 2	NCT00546936	Oct 2007 → Oct 2009	histoplasmosis retinitis	Barnes Retina Institute	Unknown	No outcome recorded
Phase 2	NCT00510965	Aug 2007 → Apr 2010	choroidal neovascularization	University Hospital, Bonn	Completed	No outcome recorded
Phase 2	NCT00504400	Aug 2007 → Jun 2009	macular telangiectasia type 2	University Hospital, Bonn	Completed	No outcome recorded
Phase 2	NCT00492284	Jul 2007 → May 2009	choroidal neovascularization, macular degeneration	QLT Inc.	Completed	No outcome recorded
Phase 2	NCT00527475	May 2007 → Jan 2010	macular degeneration	Texas Retina Associates	Completed	No outcome recorded
Phase 2	NCT00668785	Mar 2007 → Jun 2010	macular retinal edema, proliferative diabetic retinopathy	Jumper, J. Michael, M.D.	Terminated	No outcome recorded
Phase 2	NCT00457678	Jan → Dec 2007	age-related macular degeneration	Vitreous -Retina- Macula Consultants of New York	Withdrawn	No outcome recorded
Phase 2	NCT00407381	Dec 2006 → Aug 2010	diabetic macular edema	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT00413829	Oct 2006 → May 2007	age-related macular degeneration	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
Phase 2	NCT00390208	Aug 2006 → Dec 2008	age-related macular degeneration	Bay Area Retina Associates	Completed	No outcome recorded
Phase 2	NCT00387582	Jul 2006 → Feb 2009	diabetic macular edema	Rocky Mountain Retina Consultants	Completed	No outcome recorded
Phase 2	NCT00284050	Oct 2005 → Jun 2008	diabetic macular edema	Novartis	Completed	No outcome recorded
Phase 2	NCT00288561	Nov 2004 → Jul 2007	age-related macular degeneration	Novartis	Completed	No outcome recorded
Phase 2	NCT00344227	Aug 2004 → Apr 2007	wet macular degeneration	University of Miami	Completed	No outcome recorded
Phase 2	NCT00373659	Aug 2004 → Jun 2007	wet macular degeneration	University of Miami	Completed	No outcome recorded
Phase 2	NCT02127684	? → Aug 2015	diabetic macular edema	Maturi, Raj K., M.D., P.C.	Withdrawn	No outcome recorded

Phase 2/39 trials
Phase 2/3	NCT02328118	Feb 2015 → Mar 2017	proliferative diabetic retinopathy	JUNYAN ZHANG	Unknown	No outcome recorded
Phase 2/3	NCT01941329	Apr 2014 → Apr 2016	proliferative diabetic retinopathy	Association for Innovation and Biomedical Research on Light and Image	Completed	No outcome recorded
Phase 2/3	NCT01402544	Jul 2011 → Mar 2015	age-related macular degeneration	University of California, San Diego	Terminated	No outcome recorded
Phase 2/3	NCT01030770	Jul 2010 → Dec 2015	diabetic retinopathy	King's College Hospital NHS Trust	Completed	No outcome recorded
Phase 2/3	NCT00885794	May 2008 → May 2011	diabetic macular edema	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery	Unknown	No outcome recorded
Phase 2/3	NCT00626782	Jan 2008 → Apr 2011	glaucoma	Wills Eye	Completed	No outcome recorded
Phase 2/3	NCT00433017	May 2007 → Jul 2009	choroidal neovascularization, macular degeneration	Novartis	Terminated	No outcome recorded
Phase 2/3	NCT00384449	Oct 2006 → Apr 2009	Eales disease	Oregon Health and Science University	Completed	No outcome recorded
Phase 2/3	NCT00930189	Apr 2006	choroidal neovascularization	Asociación para Evitar la Ceguera en México	Withdrawn	No outcome recorded
Phase 371 trials
Phase 3	NCT06847542	Nov 2025 → Nov 2028 expected	wet macular degeneration	Hoffmann-La Roche	Recruiting	No outcome recorded
Phase 3	NCT07007065	Nov 2025 → Mar 2033 expected	wet macular degeneration	AbbVie	Recruiting	No outcome recorded
Phase 3	NCT05562947	Jun 2024 → Jul 2027 expected	wet macular degeneration	Hoffmann-La Roche	Recruiting	No outcome recorded
Phase 3	NCT05126966	Dec 2023 → Jan 2025	wet macular degeneration	Hoffmann-La Roche	Withdrawn	No outcome recorded
Phase 3	NCT04667039	Mar 2022 → Aug 2024	wet macular degeneration	AO GENERIUM	Unknown	No outcome recorded
Phase 3	NCT05138029	Nov 2021 → Dec 2023	diabetic retinopathy	Affiliated Hospital of Nantong University	Unknown	No outcome recorded
Phase 3	NCT04657289	Jul 2021 → Jan 2027 expected	wet macular degeneration	Hoffmann-La Roche	Active not recruiting	No outcome recorded
Phase 3	NCT04757610	Mar 2021 → Mar 2025	wet macular degeneration	Opthea Limited	Terminated	No outcome recorded
Phase 3	NCT04503551	Aug 2020 → Oct 2022	diabetic retinopathy	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT04108156	Sep 2019 → Jul 2027 expected	diabetic macular edema	Hoffmann-La Roche	Active not recruiting	No outcome recorded
Phase 3	NCT04063358	Aug 2019 → Aug 2021	cataract, diabetic macular edema	Second Military Medical University	Unknown	No outcome recorded
Phase 3	NCT03805100	Apr 2019 → May 2021	age-related macular degeneration	Xbrane Biopharma AB	Completed	No outcome recorded
Phase 3	NCT03683251	Sep 2018 → Dec 2029 expected	wet macular degeneration	Hoffmann-La Roche	Recruiting	No outcome recorded
Phase 3	NCT03677934	Sep 2018 → May 2020	wet macular degeneration	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT03452657	Apr 2018 → Jun 2019	diabetic retinopathy	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Unknown	No outcome recorded
Phase 3	NCT02914626	Oct 2016 → Oct 2017	neovascular glaucoma	LEANDRO CABRAL ZACHARIAS	Unknown	No outcome recorded
Phase 3	NCT02640664	Jun 2016 → Apr 2022	retinopathy of prematurity	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02375971	Dec 2015 → Dec 2017	retinopathy of prematurity	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02611778	Dec 2015 → Dec 2017	wet macular degeneration	Bioeq GmbH	Completed	No outcome recorded
Phase 3	NCT02447185	Jun 2015 → Dec 2020	proliferative diabetic retinopathy	JUNYAN ZHANG	Unknown	No outcome recorded
Phase 3	NCT02262260	Dec 2014 → Sep 2017	diabetic macular edema	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02259088	Nov 2014 → Jan 2017	diabetic macular edema, vision disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02034006	Jun 2014 → Jul 2016	choroidal neovascularization	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02032173	May 2014 → Apr 2015	diabetes mellitus, diabetic macular edema, macular degeneration	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT02641457	Mar 2014 → Mar 2015	glaucoma, rubeosis iridis	Instituto de Olhos de Goiania	Completed	No outcome recorded
Phase 3	NCT01976312	Nov 2013 → Mar 2016	central retinal vein occlusion	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01976338	Nov 2013 → Mar 2016	occlusion of tributary of retinal vein	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01846299	Oct 2013 → Sep 2015	macular retinal edema	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01908816	Sep 2013 → Jan 2016	choroidal neovascularization, diabetic retinopathy, macular retinal edema, neovascular glaucoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01922102	Sep 2013 → Sep 2016	degenerative myopia	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01840410	Sep 2013 → Nov 2015	choroidal neovascularization	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01780935	Jun 2013 → Jul 2015	wet macular degeneration	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01748292	Dec 2012 → Feb 2017	macular degeneration	Charles C Wykoff, PhD, MD	Completed	No outcome recorded
Phase 3	NCT01599650	May 2012 → May 2015	occlusion of tributary of retinal vein	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01489189	Mar 2012 → Jan 2015	proliferative diabetic retinopathy	Jaeb Center for Health Research	Completed	No outcome recorded
Phase 3	NCT01535261	Feb 2012 → Mar 2015	central retinal vein occlusion, macular retinal edema	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01396083	Aug 2011 → Jan 2014	central retinal vein occlusion, macular retinal edema, vision disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01396057	Jul 2011 → Jun 2013	macular retinal edema, occlusion of tributary of retinal vein, vision disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01377597	Jun 2011 → Apr 2012	retinal vein occlusion	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01217944	Oct 2010 → Aug 2012	myopia	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01171976	Sep 2010 → Apr 2013	diabetic macular edema	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01198327	Aug 2010 → Dec 2012	retinal vein occlusion	Peter A Campochiaro, MD	Completed	No outcome recorded
Phase 3	NCT01135914	Jul 2010 → Mar 2013	diabetic macular edema	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01131585	Jun 2010 → Jul 2011	diabetic macular edema	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT00989989	Sep 2009 → Aug 2011	diabetic macular edema	Novartis	Completed	No outcome recorded
Phase 3	NCT00891735	Jul 2009 → Aug 2011	age-related macular degeneration	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT01189526	Jan 2009 → Aug 2010	occlusion of tributary of retinal vein	Seoul Retina Investigator Group	Unknown	No outcome recorded
Phase 3	NCT00826371	Jan 2009 → Jul 2010	wet macular degeneration	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00942864	Dec 2008 → Dec 2009	macular retinal edema, retinal vein occlusion	Novartis	Completed	No outcome recorded
Phase 3	NCT00687804	May 2008 → Jan 2010	diabetic macular edema	Novartis	Completed	No outcome recorded
Phase 3	NCT00593450	Feb 2008 → Dec 2010	age-related macular degeneration	University of Pennsylvania	Completed	No outcome recorded
Phase 3	NCT00680225	Sep 2007 → Jul 2012	malignant choroid melanoma	New England Retina Associates	Completed	No outcome recorded
Phase 3	NCT00516464	Aug 2007 → Aug 2008	proliferative diabetic retinopathy	Retina Associates, Kansas City	Unknown	No outcome recorded
Phase 3	NCT00486018	Jul 2007 → May 2009	macular retinal edema, retinal vein occlusion	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT00485836	Jul 2007 → Jun 2009	macular retinal edema, retinal vein occlusion	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT01255774	Jun 2007 → Dec 2012	wet macular degeneration	The New York Eye & Ear Infirmary	Unknown	No outcome recorded
Phase 3	NCT00470678	Jun 2007 → Nov 2008	age-related macular degeneration, choroidal neovascularization	Novartis	Completed	No outcome recorded
Phase 3	NCT00473330	Jun 2007 → Nov 2010	diabetes mellitus, diabetic macular edema	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT00473382	Jun 2007 → Jan 2011	diabetes mellitus, macular retinal edema	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT00469352	May 2007 → Apr 2010	macular degeneration	Oregon Health and Science University	Completed	No outcome recorded
Phase 3	NCT00444600	Mar 2007 → Dec 2009	diabetic macular edema	Jaeb Center for Health Research	Completed	No outcome recorded
Phase 3	NCT00445003	Mar 2007 → Oct 2009	diabetic macular edema, proliferative diabetic retinopathy	Jaeb Center for Health Research	Completed	No outcome recorded
Phase 3	NCT00436553	Feb 2007 → Oct 2009	choroidal neovascularization, macular degeneration	Novartis	Completed	No outcome recorded
Phase 3	NCT00967213	Aug 2006 → Feb 2008	wet macular degeneration	Novartis	Completed	No outcome recorded
Phase 3	NCT00331864	Apr 2006 → Apr 2008	age-related macular degeneration, choroidal neovascularization	Novartis	Completed	No outcome recorded
Phase 3	NCT00275821	Dec 2005 → Jan 2008	age-related macular degeneration	Novartis	Completed	No outcome recorded
Phase 3	NCT00251459	Nov 2005 → Sep 2007	age-related macular degeneration, choroidal neovascularization	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT00090623	Aug 2004 → Mar 2007	macular degeneration	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT00061594	May 2003 → Sep 2006	macular degeneration	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT00056836	Mar 2003 → Dec 2005	age-related macular degeneration	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT00095433	Sep 2002 → Aug 2006	age-related macular degeneration	Genentech, Inc.	Completed	No outcome recorded

Phase 477 trials
Phase 4	NCT07690800	Apr 2025 → Mar 2026	retinal vascular disorder	Benha University	Completed	No outcome recorded
Phase 4	NCT06708624	Jun → Aug 2024	age-related macular degeneration, central retinal vein occlusion with macular edema	Formycon AG	Completed	No outcome recorded
Phase 4	NCT04075136	Mar 2023 → Nov 2024	wet macular degeneration	Wake Forest University Health Sciences	Withdrawn	No outcome recorded
Phase 4	NCT06234514	Jan 2023 → May 2025	cystoid macular edema	Dongyang People's Hospital	Completed	No outcome recorded
Phase 4	NCT04464694	Sep 2020 → Dec 2021	diabetic macular edema, proliferative diabetic retinopathy	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Unknown	No outcome recorded
Phase 4	NCT04062370	Oct 2019 → Aug 2022	retinal vein occlusion	Sun Yat-sen University	Unknown	No outcome recorded
Phase 4	NCT03999125	Jun 2019 → Jun 2021	diabetic macular edema	Sudhalkar Eye Hospital	Unknown	No outcome recorded
Phase 4	NCT03690947	Oct 2018 → Aug 2021	diabetic macular edema	Beijing Hospital	Completed	No outcome recorded
Phase 4	NCT03759860	Jan 2018 → Jul 2019	diabetic macular edema	CynosureLutronic	Unknown	No outcome recorded
Phase 4	NCT03148132	May 2017 → Aug 2018	retinopathy of prematurity	Autonomous University of San Luis Potosí	Completed	No outcome recorded
Phase 4	NCT03097068	Apr → Dec 2017	diabetic macular edema	Vitreo-Retinal Associates, Michigan	Completed	No outcome recorded
Phase 4	NCT03056092	Feb 2017 → Feb 2024	diabetic macular edema, macular retinal edema, retinal vein occlusion, wet macular degeneration	Unity Health Toronto	Unknown	No outcome recorded
Phase 4	NCT02806752	Jan 2017 → Dec 2018	wet macular degeneration	Aier School of Ophthalmology, Central South University	Unknown	No outcome recorded
Phase 4	NCT02953938	Dec 2016 → Dec 2018	occlusion of tributary of retinal vein	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02976194	Nov 2016 → Nov 2019	perifoveal exudative vascular anomalous complex, wet macular degeneration	Pusan National University Hospital	Unknown	No outcome recorded
Phase 4	NCT02864472	Sep 2016 → Jun 2018	age-related macular degeneration	Seoul National University Hospital	Unknown	No outcome recorded
Phase 4	NCT02878681	Sep 2016 → Sep 2017	diabetic macular edema	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 4	NCT02843490	Aug 2016 → Aug 2017	wet macular degeneration	Johannes Gutenberg University Mainz	Completed	No outcome recorded
Phase 4	NCT02834663	Aug 2016 → Feb 2019	diabetic retinopathy	Wonkwang University Hospital	Completed	No outcome recorded
Phase 4	NCT02944227	Mar 2016 → Feb 2017	wet macular degeneration	Seoul National University Hospital	Completed	No outcome recorded
Phase 4	NCT02634970	Mar 2016 → Dec 2017	wet macular degeneration	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 4	NCT02665689	Jan 2016 → Sep 2018	cystoid macular edema, transient refractive change	Prof. Dr. Antonia M. Joussen	Terminated	No outcome recorded
Phase 4	NCT02577107	Jan → Jul 2016	age-related macular degeneration	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02258009	Oct 2015 → Oct 2016	diabetic macular edema	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 4	NCT02522897	Aug 2015 → Jan 2018	central retinal vein occlusion with macular edema	PD. Dr. med. Armin Wolf	Unknown	No outcome recorded
Phase 4	NCT02462304	Jun 2015 → Jun 2017	diabetic macular edema	The University of Hong Kong	Unknown	No outcome recorded
Phase 4	NCT02140411	Apr 2015 → Dec 2016	age-related macular degeneration, retinal vein occlusion	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02257632	Apr 2015 → Mar 2017	wet macular degeneration	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02366468	Feb 2015 → Jun 2017	diabetic retinopathy	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02161575	Aug 2014 → Sep 2017	wet macular degeneration	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02059772	Apr 2014 → Nov 2017	diabetic macular edema	GWT-TUD GmbH	Unknown	No outcome recorded
Phase 4	NCT02130024	Apr 2014 → Nov 2017	age-related macular degeneration	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02131350	Apr 2014 → Mar 2017	diabetic macular edema	Shinshu University	Completed	No outcome recorded
Phase 4	NCT01986907	Mar 2014 → Jun 2016	wet macular degeneration	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02055911	Mar 2014 → Mar 2015	diabetic macular edema	Federal University of São Paulo	Withdrawn	No outcome recorded
Phase 4	NCT02478515	Jan 2014 → Mar 2019	occlusion of tributary of retinal vein	Nagoya City University	Completed	No outcome recorded
Phase 4	NCT02321839	Jan 2014 → Mar 2019	age-related macular degeneration	Nagoya City University	Completed	No outcome recorded
Phase 4	NCT02810808	Dec 2013 → Sep 2016	wet macular degeneration	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Unknown	No outcome recorded
Phase 4	NCT01972789	Oct 2013 → Feb 2017	choroidal neovascularization	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01958918	Oct 2013 → Nov 2016	wet macular degeneration	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01846273	Aug 2013 → Mar 2016	age-related macular degeneration, perifoveal exudative vascular anomalous complex	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01827722	May 2013 → May 2016	central retinal vein occlusion, macular retinal edema	Valley Retina Institute	Unknown	No outcome recorded
Phase 4	NCT01824043	Mar → Sep 2013	proliferative diabetic retinopathy	Hospital Regional de São José - Dr. Homero de Miranda Gomes	Unknown	No outcome recorded
Phase 4	NCT01775124	Feb 2013 → Nov 2015	wet macular degeneration	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01795209	Jan 2013 → Dec 2017	macular retinal edema, retinal vein occlusion	Seoul National University Bundang Hospital	Terminated	No outcome recorded
Phase 4	NCT02647515	Jan 2013 → Dec 2014	diabetic retinopathy, neovascular glaucoma	Ruijin Hospital	Completed	No outcome recorded
Phase 4	NCT01710839	Oct 2012 → Oct 2015	retinal vein occlusion	Charles C Wykoff, PhD, MD	Completed	No outcome recorded
Phase 4	NCT01669447	Sep → Nov 2012	degeneration of macula and posterior pole	Osias Francisco de Souza	Unknown	No outcome recorded
Phase 4	NCT01580020	May 2012 → Oct 2014	retinal vein occlusion	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02005432	Feb 2012 → Nov 2014	proliferative diabetic retinopathy	University of Sao Paulo	Unknown	No outcome recorded
Phase 4	NCT01453920	Nov 2011 → Jul 2012	wet macular degeneration	University Health Network, Toronto	Completed	No outcome recorded
Phase 4	NCT03409250	Jun 2011 → Jul 2014	age-related macular degeneration, choroidal neovascularization	Vista Klinik	Completed	No outcome recorded
Phase 4	NCT01306981	Mar 2011 → Mar 2013	diabetic retinopathy	Moorfields Eye Hospital NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT01315275	Feb 2011 → Aug 2012	macular retinal edema, vision disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01277302	Feb 2011 → Oct 2012	macular retinal edema	Genentech, Inc.	Completed	No outcome recorded
Phase 4	NCT01297569	Jan 2011 → Nov 2012	diabetic macular edema	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01257815	Jan 2011 → Apr 2013	diabetic macular edema	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT03393767	Dec 2010 → Oct 2016	age-related macular degeneration, choroidal neovascularization	Vista Klinik	Completed	No outcome recorded
Phase 4	NCT01500915	Nov 2010 → Mar 2012	wet macular degeneration	Institut de la Macula y la Retina	Completed	No outcome recorded
Phase 4	NCT01810042	Oct 2010 → Feb 2013	wet macular degeneration	Pusan National University Hospital	Completed	No outcome recorded
Phase 4	NCT01223612	Oct 2010 → Jul 2012	diabetic retinopathy	Moorfields Eye Hospital NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT01831947	Apr 2010 → Mar 2013	age-related macular degeneration	Institute of Application-oriented Research and Clinical Trials GmbH	Completed	No outcome recorded
Phase 4	NCT01148511	Feb 2010 → Apr 2012	age-related macular degeneration	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01213667	Jan 2010 → Dec 2017	macular degeneration	University of Cologne	Unknown	No outcome recorded
Phase 4	NCT01006538	Nov 2009 → Mar 2015	macular degeneration	King's College Hospital NHS Trust	Completed	No outcome recorded
Phase 4	NCT01246089	Jul 2009 → Oct 2014	choroidal neovascularization	Instituto de Olhos de Goiania	Unknown	No outcome recorded
Phase 4	NCT01127360	Mar 2009 → Aug 2014	wet macular degeneration	Oslo University Hospital	Completed	No outcome recorded
Phase 4	NCT01922154	Feb 2009 → Dec 2012	neovascular glaucoma	Siriraj Hospital	Completed	No outcome recorded
Phase 4	NCT00976222	Dec 2008 → Dec 2014	retinal detachment	University Hospital Muenster	Completed	No outcome recorded
Phase 4	NCT01464723	May 2008 → Dec 2011	age-related macular degeneration	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT00674323	Apr 2008 → May 2009	perifoveal exudative vascular anomalous complex	Novartis	Completed	No outcome recorded
Phase 4	NCT01628354	Feb 2008 → Apr 2010	choroidal neovascularization, retinal detachment	University of Melbourne	Completed	No outcome recorded
Phase 4	NCT01027481	Dec 2007 → Nov 2009	retinal vein occlusion	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT00504959	Jul 2007 → Jan 2010	age-related macular degeneration, choroidal neovascularization	Novartis	Completed	No outcome recorded
Phase 4	NCT00473642	May 2007 → May 2009	age-related macular degeneration, choroidal neovascularization	Oklahoma State University Center for Health Sciences	Completed	No outcome recorded
Phase 4	NCT00540930	Apr 2007 → Apr 2009	retinal vascular disorder, toxic maculopathy, uveal melanoma	Shields, Shields and Associates	Unknown	No outcome recorded
Phase 4	NCT00423189	Jan 2007 → Jan 2009	age-related macular degeneration	David M. Brown, M.D.	Terminated	No outcome recorded

Phase not applicable31 trials
—	NCT07249216	Jul 2025 → Jun 2029 expected	age-related macular degeneration	Singapore National Eye Centre	Recruiting	No outcome recorded
—	NCT04601675	Oct 2020 → Mar 2021	diabetic macular edema	He Eye Hospital	Unknown	No outcome recorded
—	NCT03115255	May 2017 → May 2018	perinatal disease	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
—	NCT03054766	Feb 2017 → Feb 2018	retinal vein occlusion	Beijing Hospital	Completed	No outcome recorded
—	NCT02857491	Jul 2014 → Sep 2017	proliferative diabetic retinopathy	Sun Yat-sen University	Completed	No outcome recorded
—	NCT02328209	Jun 2014 → Dec 2016	wet macular degeneration	Mie University	Unknown	No outcome recorded
—	NCT02144662	Mar 2014 → Jan 2017	—	St. Marianna University School of Medicine	Completed	No outcome recorded
—	NCT02169648	Dec 2013 → Dec 2015	central retinal vein occlusion, macular retinal edema, occlusion of tributary of retinal vein	Tokyo Medical University	Unknown	No outcome recorded
—	NCT02091505	Dec 2013 → May 2016	central retinal vein occlusion	Mie University	Unknown	No outcome recorded
—	NCT02158624	Dec 2013 → Apr 2015	age-related macular degeneration	Kyushu University	Unknown	No outcome recorded
—	NCT01968616	Sep 2013 → Sep 2019	retinal vein occlusion	Kyoto University, Graduate School of Medicine	Unknown	No outcome recorded
—	NCT03459144	Dec 2012 → Jul 2015	—	Sun Yat-sen University	Completed	No outcome recorded
—	NCT01626339	Apr → Jun 2012	age-related macular degeneration	University of Malaya	Unknown	No outcome recorded
—	NCT01363570	Jan 2012 → Oct 2014	wet macular degeneration	McMaster University	Completed	No outcome recorded
—	NCT01638858	Oct 2011 → Jul 2014	age-related macular degeneration	University of Luebeck	Completed	No outcome recorded
—	NCT01676506	Oct 2011 → Oct 2013	age-related macular degeneration	Russian Academy of Medical Sciences	Unknown	No outcome recorded
—	NCT01581151	Sep 2011 → Jun 2015	retinal vein occlusion	Brian Burke, MPH	Unknown	No outcome recorded
—	NCT01360151	Feb → May 2011	perifoveal exudative vascular anomalous complex	Seoul St. Mary's Hospital	Unknown	No outcome recorded
—	NCT02164604	Jan 2011 → Oct 2013	retinopathy of prematurity	Kantonsspital Aarau	Completed	No outcome recorded
—	NCT01238393	Nov 2010 → Nov 2011	preretinal fibrosis	Queen's University	Completed	No outcome recorded
—	NCT01269151	Oct 2010 → Mar 2013	age-related macular degeneration	University of Luebeck	Completed	No outcome recorded
—	NCT00618644	Jan 2010 → Jun 2011	retinal disorder, sickle cell disease	Kresge Eye Institute	Withdrawn	No outcome recorded
—	NCT00892398	Mar 2009 → Oct 2013	glaucoma	Maisonneuve-Rosemont Hospital	Completed	No outcome recorded
—	NCT01370135	Nov 2008 → Apr 2011	neovascular glaucoma, rubeosis iridis	University of Luebeck	Completed	No outcome recorded
—	NCT01442064	Jul 2008 → Jul 2010	macular retinal edema, retinal vein occlusion	Genentech, Inc.	Completed	No outcome recorded
—	NCT00709657	Mar 2008 → Jul 2010	macular degeneration	Medical University of Vienna	Terminated	No outcome recorded
—	NCT00562406	Nov 2007 → Sep 2010	macular retinal edema	Klinikum Ludwigshafen	Completed	No outcome recorded
—	NCT00640640	Aug 2007 → Dec 2008	wet macular degeneration	Sheba Medical Center	Unknown	No outcome recorded
—	NCT00539734	Aug 2007 → Dec 2008	age-related macular degeneration	Prince of Songkla University	Completed	No outcome recorded
—	NCT00726973	Dec 2006 → Jul 2012	macular retinal edema	Lahey Clinic	Withdrawn	No outcome recorded
—	NCT00379795	Apr 2005 → Sep 2008	choroidal neovascularization	Genentech, Inc.	Completed	No outcome recorded

Also used as a comparator or background therapy in 188 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT02457975 Background	Jun 2015 → Aug 2019	diabetic retinopathy	Medical College of Wisconsin	Completed	No outcome recorded
Phase 117 trials
Phase 1	NCT04884399 Comparator	Jun 2021 → Dec 2022	wet macular degeneration	Shanghai Biomabs Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT06771271 Background	Jul 2019 → Nov 2023	diabetic macular edema, macular retinal edema	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT03630315 Background	Feb 2019 → Jan 2024	wet macular degeneration	Ocular Therapeutix, Inc.	Completed	No outcome recorded
Phase 1	NCT03585556 Background	Sep 2018 → Jan 2020	wet macular degeneration	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT03312283 Comparator	Dec 2017 → Apr 2019	wet macular degeneration	Qilu Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02281292 Background	Dec 2015 → Jun 2017	diabetic macular edema	Alcon Research	Withdrawn	No outcome recorded
Phase 1	NCT02022540 Background	Feb 2014 → Mar 2016	wet macular degeneration	PanOptica, Inc.	Completed	No outcome recorded
Phase 1	NCT02591914 Background	Feb 2014 → May 2016	wet macular degeneration	Retinal Consultants of Arizona	Completed	No outcome recorded
Phase 1	NCT01334879 Comparator	May 2011 → Nov 2012	retinal vascular disorder	The New York Eye Cancer Center	Completed	No outcome recorded
Phase 1	NCT01225146 Comparator	Oct 2010 → Aug 2012	ischemic disease, retinal vein occlusion	David M. Brown, M.D.	Terminated	No outcome recorded
Phase 1	NCT01028248 Comparator	Jan 2010 → Jun 2012	central retinal vein occlusion	California Retina Consultants	Completed	No outcome recorded
Phase 1	NCT00749021 Comparator	Sep 2008 → Aug 2012	retinal detachment	Clement K. Chan	Completed	No outcome recorded
Phase 1	NCT00538538 Comparator	Sep 2007 → Oct 2008	age-related macular degeneration, retinal vascular disorder	Corewell Health East	Withdrawn	No outcome recorded
Phase 1	NCT00403156 Background	Nov 2006 → ?	choroidal neovascularization	Vitreous -Retina- Macula Consultants of New York	Withdrawn	No outcome recorded
Phase 1	NCT00406796 Comparator	Jan 2006 → Sep 2008	central retinal vein occlusion	California Retina Consultants	Completed	No outcome recorded
Phase 1	NCT00395551 Comparator	Dec 2005 → Jun 2009	choroidal neovascularization	Ophthalmic Consultants of Boston	Completed	No outcome recorded
Phase 1	NCT00406471 Comparator	May 2005 → Jan 2011	central retinal vein occlusion	Greater Houston Retina Research	Completed	No outcome recorded

Phase 1/219 trials
Phase 1/2	NCT02448446 Comparator	Aug 2015 → May 2018	diabetic macular edema	South Coast Retina Center; Carson, McBeath, Boswell, Inc.	Completed	No outcome recorded
Phase 1/2	NCT02398500 Comparator	Jul 2015 → Feb 2016	age-related macular degeneration	Alcon Research	Terminated	No outcome recorded
Phase 1/2	NCT02302989 Comparator	May 2015 → Jul 2018	age-related macular degeneration	Leonard Feiner, MD, PhD	Completed	No outcome recorded
Phase 1/2	NCT02140151 Comparator	Sep 2014 → Jul 2020	age-related macular degeneration	Southern California Desert Retina Consultants, MC	Completed	No outcome recorded
Phase 1/2	NCT01934556 Comparator	Nov 2013 → Apr 2017	diabetic macular edema	Palmetto Retina Center, LLC	Completed	No outcome recorded
Phase 1/2	NCT01972763 Comparator	Oct 2013 → Jul 2018	wet macular degeneration	Northern California Retina Vitreous Associates	Completed	No outcome recorded
Phase 1/2	NCT01926977 Comparator	Sep 2013 → May 2014	wet macular degeneration	Arshad Khanani	Completed	No outcome recorded
Phase 1/2	NCT02614937 Background	Apr 2013 → Dec 2014	macular retinal edema, retinal vein occlusion	Ohr Pharmaceutical Inc.	Completed	No outcome recorded
Phase 1/2	NCT01674569 Background	Oct 2012 → Feb 2015	wet macular degeneration	Tyrogenex	Completed	No outcome recorded
Phase 1/2	NCT02118831 Comparator	Mar 2012 → Feb 2014	age-related macular degeneration, diabetic macular edema, retinal vein occlusion	California Retina Consultants	Completed	No outcome recorded
Phase 1/2	NCT01884597 Comparator	Nov 2010 → Aug 2014	—	Hawaii Pacific Health	Completed	No outcome recorded
Phase 1/2	NCT01304693 Comparator	Oct 2010 → Mar 2013	wet macular degeneration	Alcon Research	Completed	No outcome recorded
Phase 1/2	NCT01115556 Comparator	May 2010 → Jan 2012	age-related macular degeneration	Vitreous -Retina- Macula Consultants of New York	Completed	No outcome recorded
Phase 1/2	NCT01025232 Comparator	Dec 2009 → Jan 2013	choroidal neovascularization, wet macular degeneration	David M. Brown, M.D.	Terminated	No outcome recorded
Phase 1/2	NCT00955630 Comparator	Aug 2009 → Aug 2010	histoplasmosis retinitis	Retina Associates of Kentucky	Unknown	No outcome recorded
Phase 1/2	NCT01325181 Comparator	Jul 2009 → Sep 2012	central serous chorioretinopathy	Jang Won Heo	Completed	No outcome recorded
Phase 1/2	NCT00440609 Comparator	Mar 2007 → Nov 2012	diabetic macular edema	Philip J. ferrone, M.D.	Completed	No outcome recorded
Phase 1/2	NCT00407355 Comparator	Jan 2006 → Feb 2013	macular retinal edema, retinal vein occlusion	Peter A Campochiaro, MD	Completed	No outcome recorded
Phase 1/2	NCT00395707 Comparator	Aug 2005 → Apr 2008	macular degeneration	The National Retina Institute	Completed	No outcome recorded

Phase 242 trials
Phase 2	NCT05151731 Comparator	Dec 2021 → Nov 2024	diabetic macular edema	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT04922151 Comparator	Jun 2021 → Jan 2023	myopic macular degeneration	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT04514653 Comparator	Aug 2020 → Aug 2026 overdue	wet macular degeneration	AbbVie	Active not recruiting	No outcome recorded
Phase 2	NCT03725501 Background	Dec 2018 → Jun 2021	age-related macular degeneration	AngioLab, Inc.	Completed	No outcome recorded
Phase 2	NCT03345082 Background	Nov 2017 → May 2019	wet macular degeneration	Opthea Limited	Completed	No outcome recorded
Phase 2	NCT03362190 Background	Oct 2017 → Oct 2018	wet macular degeneration	Ophthotech Corporation	Completed	No outcome recorded
Phase 2	NCT03211234 Comparator	Jul 2017 → Dec 2019	age-related macular degeneration	Santen Inc.	Completed	No outcome recorded
Phase 2	NCT03161652 Background	May 2017 → Dec 2026 expected	diabetic macular edema	Carmen Clapp	Recruiting	No outcome recorded
Phase 2	NCT03038880 Comparator	Jan 2017 → Jan 2018	age-related macular degeneration, choroidal neovascularization	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT02699450 Comparator	Apr 2016 → Sep 2017	diabetic macular edema	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT02511613 Comparator	Jul 2015 → Apr 2016	age-related macular degeneration	Ohr Pharmaceutical Inc.	Withdrawn	No outcome recorded
Phase 2	NCT02067013 Comparator	Jul 2015 → Jul 2017	macular degeneration, macular holes, neovascular glaucoma, proliferative diabetic retinopathy	California Retina Consultants	Unknown	No outcome recorded
Phase 2	NCT02348359 Background	Mar 2015 → Dec 2017	age related macular degeneration 10, wet macular degeneration	Tyrogenex	Terminated	No outcome recorded
Phase 2	NCT02397954 Background	Mar → Oct 2015	—	Ophthotech Corporation	Completed	No outcome recorded
Phase 2	NCT02355028 Background	Mar 2015 → Sep 2016	wet macular degeneration	Alcon, a Novartis Company	Completed	No outcome recorded
Phase 2	NCT02363621 Comparator	Jan 2015 → Oct 2017	diabetic macular edema	Arshad Khanani	Completed	No outcome recorded
Phase 2	NCT02222207 Comparator	Oct 2014 → May 2015	macular degeneration	Bayer	Terminated	No outcome recorded
Phase 2	NCT02181504 Comparator	Sep 2014 → Dec 2015	macular degeneration	Allergan	Completed	No outcome recorded
Phase 2	NCT02186119 Comparator	Jul 2014 → Jun 2015	macular retinal edema	Allergan	Completed	No outcome recorded
Phase 2	NCT02214628 Background	Jul 2014 → Dec 2016	age-related macular degeneration	Ophthotech Corporation	Terminated	No outcome recorded
Phase 2	NCT02181517 Comparator	Jul 2014 → Mar 2015	age-related macular degeneration	Allergan	Completed	No outcome recorded
Phase 2	NCT01994291 Comparator	Nov 2013 → Aug 2015	diabetic macular edema	Pfizer	Terminated	No outcome recorded
Phase 2	NCT01849692 Comparator	Jun 2013 → Jan 2015	wet macular degeneration	Alcon Research	Completed	No outcome recorded
Phase 2	NCT01492400 Comparator	Mar 2012 → Feb 2014	diabetic macular edema	Allergan	Completed	No outcome recorded
Phase 2	NCT01472510 Comparator	Dec 2011 → Jul 2013	diabetic macular edema	Vitreo-Retinal Associates, PC	Completed	No outcome recorded
Phase 2	NCT01162746 Comparator	Oct 2011 → Jun 2015	age-related macular degeneration, choroidal neovascularization	Medical University of Vienna	Completed	No outcome recorded
Phase 2	NCT01397409 Comparator	Sep 2011 → Mar 2014	age-related macular degeneration	Allergan	Completed	No outcome recorded
Phase 2	NCT01157065 Comparator	Jun 2011 → Apr 2012	wet macular degeneration	Alcon Research	Completed	No outcome recorded
Phase 2	NCT01243086 Comparator	Mar 2011 → May 2015	wet macular degeneration	McMaster University	Completed	No outcome recorded
Phase 2	NCT01249937 Comparator	Jan → Jul 2011	wet macular degeneration	University Health Network, Toronto	Unknown	No outcome recorded
Phase 2	NCT01189019 Comparator	Aug 2010 → Mar 2013	retinal detachment, wet macular degeneration	Anne Fung MD	Terminated	No outcome recorded
Phase 2	NCT01251978 Comparator	Jul 2010 → Jul 2012	malignant choroid melanoma	New England Retina Associates	Completed	No outcome recorded
Phase 2	NCT01134055 Comparator	Jun 2010 → Oct 2012	age-related macular degeneration	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00992563 Comparator	Jun 2010 → May 2011	wet macular degeneration	Alcon Research	Completed	No outcome recorded
Phase 2	NCT01089517 Comparator	Mar 2010 → Jun 2012	age-related macular degeneration	Ophthotech Corporation	Completed	No outcome recorded
Phase 2	NCT00931489 Comparator	Aug 2009 → Jun 2014	age-related macular degeneration	Lawrence S. Morse, MD	Completed	No outcome recorded
Phase 2	NCT00931125 Comparator	Mar 2009 → Sep 2013	diabetic retinopathy	Attila Vajas	Unknown	No outcome recorded
Phase 2	NCT00857259 Comparator	Feb 2009 → Jul 2010	age-related macular degeneration, choroidal neovascularization	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 2	NCT00766337 Comparator	Dec 2008 → Nov 2009	age-related macular degeneration, choroidal neovascularization	Santen Inc.	Terminated	No outcome recorded
Phase 2	NCT00775411 Background	Nov 2008 → Nov 2009	age-related macular degeneration, choroidal neovascularization	Allergan	Completed	No outcome recorded
Phase 2	NCT00511706 Background	Nov 2007 → Mar 2009	age-related macular degeneration, choroidal neovascularization	Allergan	Completed	No outcome recorded
Phase 2	NCT00395057 Comparator	Jan 2007 → Oct 2008	age-related macular degeneration, choroidal neovascularization	Allergan	Terminated	No outcome recorded

Phase 2/315 trials
Phase 2/3	NCT06957080 Comparator	Apr 2025 → Mar 2027 expected	diabetic macular edema	EyeBiotech Ltd.	Active not recruiting	No outcome recorded
Phase 2/3	NCT06571045 Comparator	Aug 2024 → Sep 2026 expected	diabetic macular edema	EyeBiotech Ltd.	Active not recruiting	No outcome recorded
Phase 2/3	NCT05297292 Comparator	May 2021 → May 2023	wet macular degeneration	Mabwell (Shanghai) Bioscience Co., Ltd.	Unknown	No outcome recorded
Phase 2/3	NCT03784443 Comparator	Sep 2019 → Sep 2022	diabetes mellitus, diabetic macular edema	Imperial College London	Withdrawn	No outcome recorded
Phase 2/3	NCT04460001 Comparator	May 2019 → Aug 2021	—	Assiut University	Unknown	No outcome recorded
Phase 2/3	NCT02769169 Comparator	Aug → Sep 2018	perifoveal exudative vascular anomalous complex	Sun Yat-sen University	Terminated	No outcome recorded
Phase 2/3	NCT02296567 Comparator	Dec 2014 → Jul 2016	age-related macular degeneration	East Florida Eye Institute	Unknown	No outcome recorded
Phase 2/3	NCT01835067 Background	Sep 2014 → Nov 2019	retinal vascular disorder, wet macular degeneration	King's College Hospital NHS Trust	Completed	No outcome recorded
Phase 2/3	NCT02342392 Comparator	Sep 2012 → Sep 2014	pterygium	Universiti Sains Malaysia	Completed	No outcome recorded
Phase 2/3	NCT01635803 Comparator	Jun 2012 → Jun 2016	retinal vein occlusion	Academic Medical Center - University of Amsterdam	Unknown	No outcome recorded
Phase 2/3	NCT01635790 Comparator	Jun 2012 → Jun 2016	diabetic macular edema	Prof. dr. R.O. Schlingemann	Unknown	No outcome recorded
Phase 2/3	NCT00996437 Comparator	Jun 2010 → Feb 2012	proliferative diabetic retinopathy	Jaeb Center for Health Research	Completed	No outcome recorded
Phase 2/3	NCT00811200 Comparator	Sep 2009 → Jan 2012	uveal melanoma	Leiden University Medical Center	Unknown	No outcome recorded
Phase 2/3	NCT00764738 Comparator	Oct 2008 → Nov 2011	wet macular degeneration	Retina Macula Institute	Completed	No outcome recorded
Phase 2/3	NCT00590694 Comparator	Oct 2006 → Dec 2009	retinal detachment, wet macular degeneration	Pacific Eye Associates	Completed	No outcome recorded

Phase 354 trials
Phase 3	NCT07269769 Background	Apr 2026 → Dec 2031 expected	—	Tasly Pharmaceutical Group Co., Ltd	Not yet recruiting	No outcome recorded
Phase 3	NCT07695207 Background	Sep 2025 → Dec 2027 expected	wet macular degeneration	SANGMYUNG innovation	Recruiting	No outcome recorded
Phase 3	NCT06985706 Comparator	May 2025 → Nov 2028 expected	diabetic macular edema	Belfast Health and Social Care Trust	Recruiting	No outcome recorded
Phase 3	NCT07515079 Comparator	Oct 2024 → Apr 2027 expected	diabetic macular edema	Bio-Thera Solutions	Recruiting	No outcome recorded
Phase 3	NCT06305416 Comparator	Mar 2024 → Oct 2025 overdue	diabetic macular edema, macular retinal edema	Incepta Pharmaceuticals Ltd	Recruiting	No outcome recorded
Phase 3	NCT06176352 Comparator	Mar 2024 → Sep 2025	choroidal neovascularization	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT06190093 Comparator	Jan → Nov 2024	wet macular degeneration	Outlook Therapeutics, Inc.	Completed	No outcome recorded
Phase 3	NCT05480293 Comparator	Feb 2023 → Jul 2025	wet macular degeneration	Sinocelltech Ltd.	Unknown	No outcome recorded
Phase 3	NCT05520177 Comparator	Dec 2022 → Sep 2024	occlusion of tributary of retinal vein	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT06952452 Comparator	Nov 2022 → Jul 2026 overdue	wet macular degeneration	Parc de Salut Mar	Recruiting	No outcome recorded
Phase 3	NCT05439629 Comparator	Jul 2022 → Apr 2025	wet macular degeneration	Bio-Thera Solutions	Completed	No outcome recorded
Phase 3	NCT05461339 Comparator	Jun 2022 → Sep 2024 overdue	wet macular degeneration	BioDlink Biopharm Co., Ltd.	Active not recruiting	No outcome recorded
Phase 3	NCT07389577 Comparator	Mar 2022 → Dec 2023	wet macular degeneration	Jecho Biopharmaceuticals Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT05003245 Comparator	Nov 2021 → May 2024	wet macular degeneration	Shanghai Henlius Biotech	Completed	No outcome recorded
Phase 3	NCT04740671 Comparator	Jul 2021 → Dec 2024	age-related macular degeneration	Shanghai Henlius Biotech	Completed	No outcome recorded
Phase 3	NCT05217680 Comparator	May 2021 → Aug 2025	diabetic macular edema	Laboratorios Sophia S.A de C.V.	Completed	No outcome recorded
Phase 3	NCT05701124 Comparator	Nov 2020 → Nov 2022	retinopathy of prematurity	Zagazig University	Completed	No outcome recorded
Phase 3	NCT04690556 Comparator	Sep 2020 → May 2024	wet macular degeneration	Lupin Ltd.	Completed	No outcome recorded
Phase 3	NCT05033106 Comparator	Sep 2020 → Sep 2022	retinopathy of prematurity	Zagazig University	Unknown	No outcome recorded
Phase 3	NCT04444492 Background	Aug 2020 → Nov 2027 expected	central retinal vein occlusion with macular edema	University of Giessen	Active not recruiting	No outcome recorded
Phase 3	NCT05271539 Comparator	Jul 2020 → Jul 2021	diabetic macular edema	Cairo University	Completed	No outcome recorded
Phase 3	NCT03834753 Comparator	Jun 2019 → Jun 2021	wet macular degeneration	Outlook Therapeutics, Inc.	Completed	No outcome recorded
Phase 3	NCT04857177 Comparator	Oct 2018 → Mar 2021	wet macular degeneration	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT03844074 Comparator	Oct 2018 → Jul 2020	wet macular degeneration	Outlook Therapeutics, Inc.	Completed	No outcome recorded
Phase 3	NCT03150589 Comparator	Mar 2018 → May 2019	age-related macular degeneration	Samsung Bioepis Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT03203447 Comparator	Mar → Dec 2018	macular retinal edema, retinal vein occlusion	Clearside Biomedical, Inc.	Terminated	No outcome recorded
Phase 3	NCT02623426 Comparator	Mar 2017 → Oct 2021	macular retinal edema, uveitis	JHSPH Center for Clinical Trials	Completed	No outcome recorded
Phase 3	NCT02727881 Background	Apr 2016 → Dec 2017	age-related macular degeneration	Ohr Pharmaceutical Inc.	Unknown	No outcome recorded
Phase 3	NCT02698566 Background	Mar → Apr 2016	macular retinal edema	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT02462486 Comparator	Jun 2015 → Apr 2018	macular degeneration	Allergan	Completed	No outcome recorded
Phase 3	NCT02462928 Comparator	Jun 2015 → Apr 2018	macular degeneration	Allergan	Completed	No outcome recorded
Phase 3	NCT02243878 Background	Dec 2014 → Dec 2021	wet macular degeneration	King's College Hospital NHS Trust	Completed	No outcome recorded
Phase 3	NCT01948830 Comparator	Dec 2013 → Nov 2015	age-related macular degeneration, choroidal neovascularization	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01940900 Background	Aug 2013 → Dec 2016	age-related macular degeneration	Ophthotech Corporation	Terminated	No outcome recorded
Phase 3	NCT01944839 Background	Aug 2013 → Dec 2016	age-related macular degeneration	Ophthotech Corporation	Terminated	No outcome recorded
Phase 3	NCT01661946 Comparator	Aug 2012 → Jul 2013	diabetic macular edema	Queen's University	Completed	No outcome recorded
Phase 3	NCT01627249 Comparator	Aug 2012 → Oct 2014	diabetic macular edema	Jaeb Center for Health Research	Completed	No outcome recorded
Phase 3	NCT02033031 Comparator	Aug → Nov 2012	occlusion of tributary of retinal vein	Medical University of Vienna	Completed	No outcome recorded
Phase 3	NCT03495765 Comparator	Mar 2011 → Jan 2017	diabetic macular edema	Marsden Eye Specialists	Completed	No outcome recorded
Phase 3	NCT00557791 Comparator	Nov 2009 → Jul 2011	age-related macular degeneration	OPKO Health, Inc.	Withdrawn	No outcome recorded
Phase 3	NCT01170767 Comparator	Jun 2009 → Dec 2012	age-related macular degeneration	Hospices Civils de Lyon	Completed	No outcome recorded
Phase 3	NCT01014468 Comparator	Mar → Nov 2009	age-related macular degeneration	Instituto de Olhos de Goiania	Unknown	No outcome recorded
Phase 3	NCT00559715 Comparator	Aug 2008 → Aug 2009	wet macular degeneration	Klinikum Bremen-Mitte, gGmbH	Unknown	No outcome recorded
Phase 3	NCT00710229 Comparator	Jul 2008 → Dec 2011	age-related macular degeneration	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery	Unknown	No outcome recorded
Phase 3	NCT00545870 Comparator	Jun 2008 → Mar 2013	diabetic macular edema, proliferative diabetic retinopathy	Ursula Schmidt-Erfurth, M.D.	Completed	No outcome recorded
Phase 3	NCT00637377 Comparator	Apr 2008 → Sep 2010	macular degeneration	Bayer	Completed	No outcome recorded
Phase 3	NCT00599222 Comparator	Feb 2008 → Nov 2009	wet macular degeneration	Anders Kvanta	Completed	No outcome recorded
Phase 3	NCT00499590 Comparator	Aug 2007 → Mar 2009	macular degeneration	OPKO Health, Inc.	Terminated	No outcome recorded
Phase 3	NCT00509795 Comparator	Aug 2007 → Sep 2010	macular degeneration	Regeneron Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00454389 Comparator	Apr 2007 → Sep 2011	macular degeneration	NeoVista	Unknown	No outcome recorded
Phase 3	NCT01570608 Comparator	Mar 2007 → Aug 2011	age-related macular degeneration	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery	Completed	No outcome recorded
Phase 3	NCT00567697 Comparator	Mar 2007 → Oct 2008	central retinal vein occlusion, macular retinal edema	Aleris Helse	Completed	No outcome recorded
Phase 3	NCT00429962 Comparator	Jul 2006 → Jun 2008	age-related macular degeneration, choroidal neovascularization	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 3	NCT02036723 Comparator	? → Mar 2016	wet macular degeneration	Biocad	Withdrawn	No outcome recorded

Phase 429 trials
Phase 4	NCT05861466 Comparator	Jan 2023 → Nov 2024	diabetic macular edema	Ain Shams University	Completed	No outcome recorded
Phase 4	NCT05386160 Comparator	Jul 2022 → Mar 2023	diabetic cataract, diabetic retinopathy	Ruijin Hospital	Unknown	No outcome recorded
Phase 4	NCT04853251 Background	Dec 2021 → Sep 2027 expected	wet macular degeneration	Genentech, Inc.	Recruiting	No outcome recorded
Phase 4	NCT04991350 Comparator	Nov 2021 → Sep 2022	diabetic macular edema, perifoveal exudative vascular anomalous complex, retinal ischemia	Cairo University	Terminated	No outcome recorded
Phase 4	NCT05282420 Comparator	Feb 2021 → Apr 2022	central retinal vein occlusion with macular edema	South Valley University	Unknown	No outcome recorded
Phase 4	NCT04698850 Background	Jan 2021 → Jan 2023	wet macular degeneration	Faculty Hospital Kralovske Vinohrady	Withdrawn	No outcome recorded
Phase 4	NCT03832179 Comparator	Nov 2018 → Sep 2023	cataract, diabetic macular edema	Bay Area Retina Associates	Completed	No outcome recorded
Phase 4	NCT03709745 Comparator	Oct 2018 → Oct 2021	occlusion of tributary of retinal vein	St. Erik Eye Hospital	Completed	No outcome recorded
Phase 4	NCT04089605 Comparator	Jun 2017 → Nov 2018	diabetic macular edema	Far Eastern Memorial Hospital	Completed	No outcome recorded
Phase 4	NCT03590444 Comparator	Apr 2017 → Apr 2018	diabetic macular edema	Hospital Hietzing	Completed	No outcome recorded
Phase 4	NCT04087746 Comparator	Jan 2017 → Jan 2019	diabetic macular edema	Minia University	Completed	No outcome recorded
Phase 4	NCT03261635 Background	Jan → Dec 2016	macular retinal edema	University of Brescia	Completed	No outcome recorded
Phase 4	NCT02684084 Comparator	Nov 2015 → Nov 2016	diabetic macular edema	North Toronto Eye Care Laser and Eye Specialists	Terminated	No outcome recorded
Phase 4	NCT02646670 Comparator	Jul → Oct 2015	retinal disorder	Instituto de Olhos de Goiania	Completed	No outcome recorded
Phase 4	NCT02527733 Comparator	Jun 2015 → Sep 2017	occlusion of tributary of retinal vein	Fukushima Medical University	Unknown	No outcome recorded
Phase 4	NCT02471651 Comparator	Jun 2015 → Oct 2018	diabetic macular edema	California Retina Consultants	Completed	No outcome recorded
Phase 4	NCT03042871 Comparator	Apr 2015 → Jul 2018	choroidal neovascularization	Zhongshan Ophthalmic Center, Sun Yat-sen University	Completed	No outcome recorded
Phase 4	NCT02107131 Comparator	Mar 2015 → May 2017	diabetic macular edema	California Retina Consultants	Completed	No outcome recorded
Phase 4	NCT03458923 Comparator	Jan 2015 → Jun 2018	diabetic macular edema	Cairo University	Unknown	No outcome recorded
Phase 4	NCT02321267 Background	Dec 2014 → Dec 2024	macular degeneration	Kagawa University	Unknown	No outcome recorded
Phase 4	NCT02274259 Comparator	Oct 2014 → Jun 2015	central retinal vein occlusion	Anders Kvanta	Completed	No outcome recorded
Phase 4	NCT01863199 Comparator	May 2013 → Nov 2015	wet macular degeneration	Retinal Consultants of Arizona	Completed	No outcome recorded
Phase 4	NCT02060604 Comparator	Dec 2012 → Jan 2014	wet macular degeneration	University of Brescia	Completed	No outcome recorded
Phase 4	NCT01427751 Comparator	Oct 2011 → Nov 2014	macular retinal edema, retinal vein occlusion	Allergan	Completed	No outcome recorded
Phase 4	NCT01319188 Comparator	Jun 2010 → Oct 2012	age-related macular degeneration, cerebrovascular disorder, coronary artery disorder	Ural State Medical University	Terminated	No outcome recorded
Phase 4	NCT01448018 Comparator	Jan 2010 → Jun 2013	central retinal vein occlusion	Centre Hospitalier Intercommunal Creteil	Completed	No outcome recorded
Phase 4	NCT00813891 Comparator	Jan → Dec 2009	macular degeneration	McGill University Health Centre/Research Institute of the McGill University Health Centre	Unknown	No outcome recorded
Phase 4	NCT00533520 Comparator	Sep 2007 → Nov 2013	choroidal neovascularization, macular degeneration	Brandon G. Busbee, MD	Completed	No outcome recorded
Phase 4	NCT00680498 Comparator	Feb 2007 → Jul 2009	age-related macular degeneration	Illinois Retina Associates	Completed	No outcome recorded

Phase not applicable11 trials
—	NCT07520045 Comparator	Mar 2026 → Jun 2027 expected	diabetic macular edema	Osijek University Hospital	Recruiting	No outcome recorded
—	NCT03944070 Comparator	Jan 2018 → Jan 2020	cataract, wet macular degeneration	Ophthalmica Eye Institute	Unknown	No outcome recorded
—	NCT02207712 Background	Nov 2014 → Aug 2023	diabetic macular edema	PolyPhotonix Medical	Terminated	No outcome recorded
—	NCT02174211 Comparator	Jun 2014 → Nov 2020	age-related macular degeneration	King's College Hospital NHS Trust	Completed	No outcome recorded
—	NCT01521819 Background	Aug 2012 → Aug 2013	age-related macular degeneration, retinal detachment	Oraya Therapeutics, Inc.	Unknown	No outcome recorded
—	NCT01640171 Background	Jul 2012 → Sep 2013	age-related macular degeneration, central retinal vein occlusion, diabetic macular edema	Retina Vitreous Associates of Florida	Completed	No outcome recorded
—	NCT01473251 Comparator	Nov 2011 → Apr 2014	diabetic macular edema, wet macular degeneration	Vitreo-Retinal Associates, Michigan	Completed	No outcome recorded
—	NCT01428388 Comparator	Sep 2011 → Oct 2015	macular retinal edema, retinal vein occlusion	Barnes Retina Institute	Completed	No outcome recorded
—	NCT00644280 Comparator	Apr 2008 → Dec 2010	glaucoma	University of California, San Francisco	Terminated	No outcome recorded
—	NCT01256632 Comparator	Oct 2007 → Oct 2010	choroidal neovascularization	Vision Research Foundation	Completed	No outcome recorded
—	NCT00455871 Comparator	Apr 2007 → Oct 2010	age-related macular degeneration	Barnes Retina Institute	Unknown	No outcome recorded

Press releases naming this drug 9 releases

Date	Issuer	Release
2022-08-29	Teva Branded Pharmaceutical Products R&D, Inc.	European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucentis®**, for age-related macular degeneration (AMD) the most common cause of blindness in developed countries tevapharm.com ↗
2022-05-17	Teva Branded Pharmaceutical Products R&D, Inc.	United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼ tevapharm.com ↗
2021-06-24	Roche Global Development	FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD) roche.com ↗
2020-07-22	Roche Global Development	Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration roche.com ↗
2020-05-27	Roche Global Development	Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration roche.com ↗
2019-07-26	Novartis Pharmaceuticals	Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness novartis.com ↗
2018-09-22	Novartis Pharmaceuticals	Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness novartis.com ↗
2017-04-18	Roche Global Development	FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States roche.com ↗
2016-12-07	Novartis Pharmaceuticals	Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions novartis.com ↗

Evidence & citations 22 cited values

Every value below carries the sentence it was read from. 512 sources stand behind the page.

Field	Value	Cited text
Known as	ranibizumab	“Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used...” NCT02457975 ↗ 473 “PURPOSE: To investigate safety and evidence of efficacy of IBI-20089, an intravitreal, liquid, sustained drug delivery system formulated with triamcinolone acetonide (TA) in...” PMID 25376617 ↗ Nov 2014 “Dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA) and Ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA) as needed group:” NCT01581151 ↗ “Recently, it's reported that intravitreal high dose Lucentis®（Ranibizumab） could benefit to both regression of the polyps and the relief of macular edema in PCV patients.” NCT02769169 ↗ “Lucentis® (ranibizumab) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.” NCT04857177 ↗ “Anti-VEGFs including ranibizumab and biosimilars, aflibercept, faricimab, and brolucizumab will be used, as per the standard of care at participating sites.” NCT06985706 ↗ “A total of 442 patients with diabetic macular edema will be randomized 1:1 to be treated with either PRO-169 (bevacizumab) or Lucentis® (ranibizumab).” NCT05217680 ↗ “0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial.” NCT01580020 ↗ “Use of Subretinal Ranibizumab (Lucentis) in the Management of Submacular Hemorrhage in Neovascular Age-Related Macular Degeneration (AMD)” NCT00538538 ↗ “Comparing the efficacy and safety of BAT5906 and Ranibizumab (Lucentis®) in Patients With Neovascular Age-related Macular Degeneration” NCT05439629 ↗ “Comparing the Efficacy and Safety of BAT5906 Versus Ranibizumab (Lucentis®) in Patients With Diabetic Macular Edema (DME)” NCT07515079 ↗ “Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy” NCT02834663 ↗ “Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2.” NCT02262260 ↗ “Lucentis (Ranibizumab) plus reduced fluence Photodynamic Therapy With Visudyne” NCT00455871 ↗ “601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)” NCT04667910 ↗ “* Loading Phase (3 months): SMZ1 BID and Ranibizumab Monthly injection;” NCT07695207 ↗ “Ranibizumab: 1 dose/study eye (Screening/Baseline), then PRN injections” NCT07269769 ↗ “Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks” NCT06305416 ↗ “This injection may be ranibizumab, bevacizumab, or aflibercept.” NCT02471651 ↗ “0.5 mg in 0.05 mL ranibizumab alone (Lucentis, by Novartis)” NCT05271539 ↗ “Intravitreous administration of Ranibizumab (Lucentis ™)” NCT01027481 ↗ “intravitreal injection Lucentis (ranibizumab)” NCT00467935 ↗ “ranibizumab sustained delivery implant” NCT01186432 ↗ “rhuFab V2 (ranibizumab)” NCT00056823 ↗ “rhuFab V2 (ranibizumab)” NCT00056836 ↗ “Other Name: Ranibizumab” NCT01899066 ↗ “Lucentis (Ranibizumab)” NCT01638858 ↗ “Ranibizumab (Lucentis)” NCT02348359 ↗ “Ranibizumab (Lucentis)” NCT03585556 ↗ “Ranibizumab” NCT02158624 ↗ “ranibizumab” NCT03630315 ↗ NCT00570193 ↗ NCT00090623 ↗ NCT01030770 ↗ NCT02806752 ↗ NCT06176352 ↗ NCT00687804 ↗ NCT05151744 ↗ NCT03054766 ↗ NCT04698850 ↗ NCT04601675 ↗ NCT03999125 ↗ NCT00750399 ↗ NCT00424710 ↗ NCT01292798 ↗ NCT01635803 ↗ NCT01500915 ↗ NCT00942864 ↗ NCT01976338 ↗ NCT01134055 ↗ NCT03832179 ↗ NCT01976312 ↗ NCT01217944 ↗ NCT01775124 ↗ NCT01972789 ↗ NCT06205979 ↗ NCT00390208 ↗ NCT01840410 ↗ NCT05861466 ↗ NCT03590444 ↗ NCT06957080 ↗ NCT01986907 ↗ NCT00626782 ↗ NCT01453920 ↗ NCT05033106 ↗ NCT01306981 ↗ NCT00331864 ↗ NCT00499590 ↗ NCT00992563 ↗ NCT01464723 ↗ NCT03148132 ↗ NCT00557791 ↗ NCT03725501 ↗ NCT00275821 ↗ NCT02257632 ↗ NCT00395707 ↗ NCT00429962 ↗ NCT01225146 ↗ NCT00378196 ↗ NCT03409250 ↗ NCT00841581 ↗ NCT01269151 ↗ NCT01972763 ↗ NCT01255774 ↗ NCT05138029 ↗ NCT00545870 ↗ NCT01914159 ↗ NCT07007065 ↗ NCT01427751 ↗ NCT05151731 ↗ NCT01315275 ↗ NCT05461339 ↗ NCT00284050 ↗ NCT00457145 ↗ NCT02843490 ↗ NCT00395551 ↗ NCT02448446 ↗ NCT00284089 ↗ NCT00896779 ↗ NCT00473642 ↗ NCT00457067 ↗ NCT02611778 ↗ NCT01448018 ↗ NCT01205035 ↗ NCT02169648 ↗ NCT00599222 ↗ NCT03784443 ↗ NCT00469352 ↗ NCT05386160 ↗ NCT00831350 ↗ NCT06771271 ↗ NCT02130024 ↗ NCT01810042 ↗ NCT01535261 ↗ NCT02050828 ↗ NCT00826371 ↗ NCT00769145 ↗ NCT00815360 ↗ NCT00440609 ↗ NCT04514653 ↗ NCT04460001 ↗ NCT04444492 ↗ NCT01676506 ↗ NCT02328118 ↗ NCT02699450 ↗ NCT00485836 ↗ NCT02296567 ↗ NCT02131350 ↗ NCT00713518 ↗ NCT01442064 ↗ NCT01428388 ↗ NCT01748292 ↗ NCT01243086 ↗ NCT00618644 ↗ NCT03071055 ↗ NCT02207712 ↗ NCT00527475 ↗ NCT02527733 ↗ NCT00363168 ↗ NCT06305416 ↗ NCT04503551 ↗ NCT00406471 ↗ NCT02646670 ↗ NCT01028248 ↗ NCT00640640 ↗ NCT01213667 ↗ NCT00657202 ↗ NCT01003106 ↗ NCT02321267 ↗ NCT06190093 ↗ NCT01011374 ↗ NCT00976222 ↗ NCT00470678 ↗ NCT01487629 ↗ NCT02067013 ↗ NCT02140411 ↗ NCT01565148 ↗ NCT01476449 ↗ NCT02060604 ↗ NCT00680498 ↗ NCT01169909 ↗ NCT02342392 ↗ NCT01127360 ↗ NCT01669447 ↗ NCT00486018 ↗ NCT02258009 ↗ NCT01069341 ↗ NCT02358889 ↗ NCT03690947 ↗ NCT02484690 ↗ NCT04657289 ↗ NCT00593450 ↗ NCT02398500 ↗ NCT00533520 ↗ NCT03495765 ↗ NCT04991350 ↗ NCT00570726 ↗ NCT04075136 ↗ NCT00667472 ↗ NCT00768963 ↗ NCT01304693 ↗ NCT00492284 ↗ NCT02055911 ↗ NCT01247220 ↗ NCT00676559 ↗ NCT01968239 ↗ NCT01599650 ↗ NCT02328209 ↗ NCT00685854 ↗ NCT04567303 ↗ NCT00095433 ↗ NCT04878835 ↗ NCT03844074 ↗ NCT00539734 ↗ NCT00395057 ↗ NCT03805100 ↗ NCT00470977 ↗ NCT01171976 ↗ NCT00661583 ↗ NCT03499223 ↗ NCT01469156 ↗ NCT00379795 ↗ NCT00885794 ↗ NCT02118831 ↗ NCT01102946 ↗ NCT01037348 ↗ NCT02447185 ↗ NCT01201161 ↗ NCT02302079 ↗ NCT00590694 ↗ NCT00826618 ↗ NCT01256632 ↗ NCT02641457 ↗ NCT01377597 ↗ NCT00606138 ↗ NCT01982435 ↗ NCT07389577 ↗ NCT00967213 ↗ NCT01248117 ↗ NCT01297569 ↗ NCT01249937 ↗ NCT00504400 ↗ NCT03115255 ↗ NCT00567697 ↗ NCT01277302 ↗ NCT00403325 ↗ NCT03038880 ↗ NCT00456495 ↗ NCT02140151 ↗ NCT01564108 ↗ NCT01122511 ↗ NCT00436553 ↗ NCT01635790 ↗ NCT02144662 ↗ NCT02032173 ↗ NCT03677934 ↗ NCT02878681 ↗ NCT02914626 ↗ NCT01795209 ↗ NCT01360151 ↗ NCT00775411 ↗ NCT03709745 ↗ NCT00403156 ↗ NCT00644280 ↗ NCT03759860 ↗ NCT02186119 ↗ NCT07690800 ↗ NCT00891735 ↗ NCT00403039 ↗ NCT03452657 ↗ NCT01396057 ↗ NCT01223612 ↗ NCT02366468 ↗ NCT04087746 ↗ NCT00061594 ↗ NCT01746563 ↗ NCT00384449 ↗ NCT04853251 ↗ NCT00546936 ↗ NCT01945866 ↗ NCT01835067 ↗ NCT01661946 ↗ NCT02623426 ↗ NCT00387582 ↗ NCT00681889 ↗ NCT02530918 ↗ NCT00685503 ↗ NCT00846625 ↗ NCT01135914 ↗ NCT00413829 ↗ NCT01238393 ↗ NCT01827722 ↗ NCT00765921 ↗ NCT01370135 ↗ NCT02614937 ↗ NCT01189526 ↗ NCT05282420 ↗ NCT01115556 ↗ NCT01941329 ↗ NCT02864472 ↗ NCT01594281 ↗ NCT02976194 ↗ NCT06234514 ↗ NCT01471691 ↗ NCT01402544 ↗ NCT05701124 ↗ NCT01884597 ↗ NCT01077401 ↗ NCT02036723 ↗ NCT00433017 ↗ NCT03683251 ↗ NCT00561834 ↗ NCT01968616 ↗ NCT01824043 ↗ NCT00668785 ↗ NCT00504959 ↗ NCT01198327 ↗ NCT02059772 ↗ NCT01628354 ↗ NCT05126966 ↗ NCT02181517 ↗ NCT01257815 ↗ NCT01489189 ↗ NCT04108156 ↗ NCT00637377 ↗ NCT01849692 ↗ NCT02161575 ↗ NCT02127684 ↗ NCT01363570 ↗ NCT01934556 ↗ NCT02222610 ↗ NCT04757610 ↗ NCT02859441 ↗ NCT00931489 ↗ NCT01908816 ↗ NCT02647515 ↗ NCT00680225 ↗ NCT03834753 ↗ NCT02511613 ↗ NCT00955630 ↗ NCT01189019 ↗ NCT01674569 ↗ NCT02222207 ↗ NCT02174211 ↗ NCT01823965 ↗ NCT02510794 ↗ NCT02810808 ↗ NCT01846273 ↗ NCT02034006 ↗ NCT00727038 ↗ NCT02462304 ↗ NCT00996437 ↗ NCT01396083 ↗ NCT00407381 ↗ NCT03042871 ↗ NCT01334879 ↗ NCT01014468 ↗ NCT02107131 ↗ NCT00540930 ↗ NCT00993525 ↗ NCT00511706 ↗ NCT00454389 ↗ NCT03423823 ↗ NCT07249216 ↗ NCT02478515 ↗ NCT02698566 ↗ NCT02091505 ↗ NCT01280929 ↗ NCT01251978 ↗ NCT02259088 ↗ NCT01968486 ↗ NCT00407355 ↗ NCT00931125 ↗ NCT00709657 ↗ NCT00516464 ↗ NCT01148511 ↗ NCT00559715 ↗ NCT00793923 ↗ NCT03763227 ↗ NCT02181504 ↗ NCT04464694 ↗ NCT01994291 ↗ NCT00674323 ↗ NCT02164604 ↗ NCT00373659 ↗ NCT01472510 ↗ NCT02857491 ↗ NCT02462928 ↗ NCT05562947 ↗ NCT01131585 ↗ NCT00423189 ↗ NCT01780935 ↗ NCT01025232 ↗ NCT02511067 ↗ NCT02522897 ↗ NCT00766337 ↗ NCT00509795 ↗ NCT00726973 ↗ NCT02294656 ↗ NCT01940900 ↗ NCT00726466 ↗ NCT00749021 ↗ NCT02462486 ↗ NCT01015495 ↗ NCT02375971 ↗ NCT06952452 ↗ NCT03973138 ↗ NCT00500344 ↗ NCT02363621 ↗ NCT01123564 ↗ NCT00498355 ↗ NCT01710839 ↗ NCT04062370 ↗ NCT01627249 ↗ NCT01610557 ↗ NCT00837330 ↗ NCT02355028 ↗ NCT00857259 ↗ NCT01948830 ↗ NCT00251459 ↗ NCT01552408 ↗ NCT00892398 ↗ NCT00805233 ↗ NCT00574093 ↗ NCT03393767 ↗ NCT03459144 ↗ NCT06571045 ↗ NCT04740671 ↗ NCT01926977 ↗ NCT01319188 ↗ NCT00510965 ↗ NCT00089765 ↗ NCT00710229 ↗ NCT02387957 ↗ NCT02640664 ↗ NCT03056092 ↗ NCT01831947 ↗ NCT04922151 ↗ NCT02281292 ↗ NCT02134457 ↗ NCT00813891 ↗ NCT02321839 ↗ NCT01162746 ↗ NCT01958918 ↗ NCT01492400 ↗ NCT02634970 ↗ NCT00444600 ↗ NCT01570608 ↗ NCT05520177 ↗ NCT03345082 ↗ NCT02243878 ↗ NCT01922154 ↗ NCT00811200 ↗ NCT02727881 ↗ NCT00764738 ↗ NCT01944839 ↗ NCT03161652 ↗ NCT01253694 ↗ NCT00445003 ↗ NCT03944070 ↗ NCT02274259 ↗ NCT00562406 ↗ NCT00517010 ↗ NCT01845844 ↗ NCT02302989 ↗ NCT01397409 ↗ NCT00473382 ↗ NCT01406639 ↗ NCT01246089 ↗ NCT02953938 ↗ NCT00406796 ↗ NCT06847542 ↗ NCT02665689 ↗ NCT01846299 ↗ NCT05248334 ↗ NCT04089605 ↗ NCT03458923 ↗ NCT02577107 ↗ NCT00473330 ↗ NCT00344227 ↗ NCT01922102 ↗ NCT01445899 ↗ NCT01112085 ↗ NCT00930189 ↗ NCT03261635 ↗ NCT01006538 ↗ NCT00989989 ↗ NCT01157065 ↗ NCT01325181 ↗ NCT03150589 ↗ NCT01626339 ↗ NCT00288561 ↗ NCT05480293 ↗ NCT07520045 ↗
Known as	(Lucentis, Ranibizumab (Novartis Pharma AG, Basel, Switzerland, and Genentech Inc., South San Francisco, CA, USA)	“(Lucentis®, Ranibizumab (Novartis Pharma AG, Basel, Switzerland, and Genentech Inc., South San Francisco, CA, USA)” NCT04089605 ↗
Known as	FYB201	“The purpose of this study is to determine the efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related...” NCT02611778 ↗ 1 NCT06708624 ↗
Known as	IVR	“Intravitreal ranibizumab (IVR) injection in patients with retinal dystrophy and macular cysts who have not responded to treatment with carbonic anhydrase inhibitors” NCT03763227 ↗
Known as	Lucenti	“Ranibizumab (Lucenti®)” NCT02646670 ↗
Known as	Lucentis	“OBJECTIVE: To examine the effects of intravitreal ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA) treatment on patient-reported vision-related function, as...” PMID 25148789 ↗ Aug 2014 102 “Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used...” NCT02457975 ↗ “PURPOSE: To investigate safety and evidence of efficacy of IBI-20089, an intravitreal, liquid, sustained drug delivery system formulated with triamcinolone acetonide (TA) in...” PMID 25376617 ↗ Nov 2014 “The purpose of this study is to evaluate the effects of intravitreal Lucentis® (Ranibizumab) and investigate the anatomical and functional improvement following this treatment...” NCT00942864 ↗ “A 24 Month Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF-BB Pegylated Aptamer) Regiment Administered in Combination With Avastin®, Eylea®, or Lucentis®) During the...” NCT02214628 ↗ “PURPOSE: To investigate the comparative efficacy of bevacizumab (Avastin) and ranibizumab (Lucentis; both Genentech, Inc, South San Francisco, CA) for diabetic macular edema...” PMID 26875003 ↗ Feb 2016 “Patients with neovascular Age-related macular degeneration (AMD) and the particular feature of pigment epithelial detachments (PEDs) were not studied in the Phase III trials...” NCT00590694 ↗ “An emerging treatment modality for CME in RP is the use of intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF) such as bevacizumab (Avastin®) and...” NCT03763227 ↗ “To investigate the effectiveness of intravitreal applications of 0.5 mg Lucentis (ranibizumab) in patients with vitreous hemorrhage due to proliferative diabetic retinopathy.” NCT01824043 ↗ “Dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA) and Ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA) as needed group:” NCT01581151 ↗ “Recently, it's reported that intravitreal high dose Lucentis®（Ranibizumab） could benefit to both regression of the polyps and the relief of macular edema in PCV patients.” NCT02769169 ↗ “Genetic factors of an individual patient may have an impact on Ranibizumab (Lucentis) treatment outcome in patients with Wet Age-Related Macular Degeneration (AMD).” NCT01676506 ↗ “Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.” NCT01171976 ↗ “enrolled to receive 3 consecutive monthly intravitreal injections of ranibizumab (0.5 mg) [Lucentis; Genentech Inc, South San Francisco, California, USA].” PMID 19376495 ↗ Apr 2009 “A total of 442 patients with diabetic macular edema will be randomized 1:1 to be treated with either PRO-169 (bevacizumab) or Lucentis® (ranibizumab).” NCT05217680 ↗ “intravitreal injection of Avastin, Lucentis, and Macugen for wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema” NCT01640171 ↗ “Use of Subretinal Ranibizumab (Lucentis) in the Management of Submacular Hemorrhage in Neovascular Age-Related Macular Degeneration (AMD)” NCT00538538 ↗ “The Ranibizumab group was treated with one intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Basel, Novartis) at baseline.” NCT05248334 ↗ “Comparing the efficacy and safety of BAT5906 and Ranibizumab (Lucentis®) in Patients With Neovascular Age-related Macular Degeneration” NCT05439629 ↗ “This study will examine whether the drug ranibizumab (Lucentis) can help prevent vision loss in people with macular telangiectasia” NCT00685503 ↗ “This study will examine whether the drug ranibizumab (Lucentis) can help prevent vision loss in people with macular telangiectasia” NCT00685854 ↗ “Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.” NCT01627249 ↗ “Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.” NCT02181517 ↗ “Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.” NCT01489189 ↗ “A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD” NCT00469352 ↗ “Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with Lucentis, Avastin or Eylea.” NCT02397954 ↗ “ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection” NCT01360151 ↗ “The substances currently in clinical use include ranibizumab (Lucentis®), bevacizumab (Avastin®) and pegaptanib (Macugen®).” NCT00709657 ↗ “Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.” NCT02186119 ↗ “Comparison of Ranibizumab (Lucentis) Monotherapy Versus Combination of Ranibizumab (Lucentis) With Photodynamic Therapy” NCT01570608 ↗ “Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.” NCT02140411 ↗ “Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen” NCT01297569 ↗ “A study using the antibody fragment Ranibizumab (Lucentis™) in patiens with diabetic macula edema is in progress.” NCT00545870 ↗ “intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)” NCT05282420 ↗ “Lucentis (ranibizumab) injection into the vitreous cavity after R:GEN laser treatment (Selective Retina Therapy)” NCT03759860 ↗ “Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2.” NCT02262260 ↗ “comparing ranibizumab (LUCENTIS) with verteporfin (VISUDYNE) photodynamic therapy (PDT)” PMID 17949673 ↗ Oct 2007 “ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33\&37 per study protocol” NCT00570193 ↗ “0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant” NCT05033106 ↗ “Lucentis (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.” NCT03805100 ↗ “intravitreal injection of anti-VEGF agent, Lucentis (Ranibizumab) is effective” NCT02091505 ↗ “Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema” NCT00826618 ↗ “Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks” NCT03150589 ↗ “Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions” NCT00407355 ↗ “Rescue treatment with intravitreal ranibizumab (Lucentis) as needed” NCT01674569 ↗ “monthly intravitreal Ranibizumab (Lucentis) injections for 9 months” NCT00406471 ↗ “Lucentis® Monotherapy (Ranibizumab 0.5 mg Intravitreal Injections)” NCT01280929 ↗ “ranibizumab (0.5mg Lucentis®; Genentech, South San Francisco, CA)” NCT03973138 ↗ “Intravitreous ranibizumab (lucentis) for radiation maculopathy.” PMID 20142553 ↗ Feb 2010 “0.5 mg in 0.05 mL ranibizumab alone (Lucentis, by Novartis)” NCT05271539 ↗ “intravitreal injection of Lucentis® (ranibizumab, 0.3 mg)” NCT00413829 ↗ “Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)” NCT01914159 ↗ “ranibizumab (Lucentis) 0.5mg intravitreal injection” NCT00403156 ↗ “0.5mg Intraocular Ranibizumab (Lucentis) Injections” NCT01269151 ↗ “Intravitreal injection with Lucentis (Ranibizumab)” NCT03409250 ↗ “0.5mg intraocular Ranibizumab (Lucentis)” NCT01370135 ↗ “rhuFab V2 [ranibizumab] ( Lucentis )” NCT00403325 ↗ “intravitreal Lucentis (Ranibizumab)” NCT02144662 ↗ “LUCENTIS (Ranibizumab Injection)” NCT04853251 ↗ “Ranibizumab Injection [Lucentis]” NCT05386160 ↗ “Ranibizumab Injection [Lucentis]” NCT06205979 ↗ “Lucentis (Ranibizumab 0.5 mg)” NCT00574093 ↗ “Lucentis® (ranibizumab 0,5mg)” NCT02032173 ↗ “Ranibizumab (Lucentis®)” NCT02646670 ↗ “Ranibizumab (Lucentis )” NCT00403039 ↗ “Ranibizumab (Lucentis)” NCT00570726 ↗ “Ranibizumab (Lucentis)” NCT01028248 ↗ “Lucentis (ranibizumab)” NCT00516464 ↗ “Ranibizumab (Lucentis)” NCT00373659 ↗ “Lucentis (ranibizumab)” NCT00500344 ↗ NCT00457678 ↗ NCT02033031 ↗ NCT03312283 ↗ NCT02944227 ↗ NCT04667039 ↗ NCT02684084 ↗ NCT01170767 ↗ NCT01089517 ↗ NCT06305416 ↗ NCT04063358 ↗ NCT04884399 ↗ NCT01521819 ↗ NCT05003245 ↗ NCT00467935 ↗ NCT01638858 ↗ NCT03927690 ↗ NCT00455871 ↗ NCT05571267 ↗ NCT02591914 ↗ NCT01473251 ↗ NCT03203447 ↗ NCT02121353 ↗ NCT07515079 ↗ NCT05297292 ↗ NCT04690556 ↗ NCT04857177 ↗ NCT02022540 ↗ NCT02543229 ↗ NCT01863199 ↗ NCT01414153 ↗ NCT03097068 ↗ NCT03211234 ↗ NCT03362190 ↗
Known as	Lucentis = ranibizumab	“Lucentis = ranibizumab” NCT00570193 ↗ 1 “Lucentis (ranibizumab)” NCT00618644 ↗
Known as	Lucentis the brand name of Ranibizumab	“Lucentis the brand name of Ranibizumab” NCT00813891 ↗
Known as	Lucentis(ranibizumab), 3mg/0.3ml	“Lucentis(ranibizumab), 3mg/0.3ml” NCT01795209 ↗
Known as	NDC # 50242-0080-01, Brand Name is Lucentis	“NDC # 50242-0080-01, Brand Name is Lucentis” NCT00387582 ↗
Known as	PF582	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02121353 ↗
Known as	Ranibizumab (Lucentis)	“Ranibizumab (Lucentis)” NCT03585556 ↗ 1 “Ranibizumab (Lucentis)” NCT02348359 ↗
Known as	Ranibizumab Ophthalmic	“Drug: Ranibizumab Ophthalmic” NCT03148132 ↗
Known as	Ranibizumabe	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02005432 ↗
Known as	RBZ	“LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME” NCT02684084 ↗ 2 “This study is being done to see if the investigational drug Ranibizumab (RBZ) given by injection into the eye, is safe and effective” NCT00407381 ↗ “Ranibizumab, RBZ (group B)” NCT06952452 ↗
Known as	RFB002	“Ranibizumab (RFB002)” NCT02259088 ↗ 1 NCT00901186 ↗
Known as	rhuFab V2	“This open-label study will pilot the use of an anti-VEGF therapy, ranibizumab (rhuFab V2) in 5 participants to investigate the potential efficacy as a treatment for retinal...” NCT00089765 ↗ 8 “Ranibizumab (rhuFab V2, an anti-VEGF agent, is a potent inhibitor of vascular permeability, with the potential to reduce retinal vascular leakage and diminish macular edema.” NCT00406796 ↗ “rhuFab V2 [ranibizumab] ( Lucentis )” NCT00403325 ↗ “rhuFab V2 (ranibizumab)” NCT00061594 ↗ “rhuFab V2 (ranibizumab)” NCT00090623 ↗ “rhuFab V2 (ranibizumab)” NCT00095433 ↗ “rhuFab V2 (ranibizumab)” NCT00251459 ↗ NCT00056823 ↗ NCT00056836 ↗
Known as	Xlucane	“Xlucane (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.” NCT03805100 ↗
Action	Inhibit	“neutralizes all active forms of vascular endothelial growth factor A” PMID 17021319 ↗ Oct 2006
Modality	Monoclonal antibody	“ranibizumab--a recombinant, humanized, monoclonal antibody Fab” PMID 17021319 ↗ Oct 2006
Route	Intravitreal	“Intravitreal Injections of rhuFab V2” NCT00056823 ↗
Target	VEGFA	“neutralizes all active forms of vascular endothelial growth factor A” PMID 17021319 ↗ Oct 2006